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CHAPfER I 
INTRODUCTION 
A stressful stimulus can be defined as a threat (real or perceived) to an 
organism's survival, integrity, or reproductive success. The adaptive biological 
reactions to such a stimulus have been termed the stress response. The animal's full 
attention and integrated action may be required in order to achieve survival and to 
eliminate the threatening stimulus. To this end, the stress response involves changes 
in several physiological and behavioral parameters. For example, activation of the 
endocrine and the autonomic nervous systems serves to increase the probability of 
survival of the organism and to terminate the stress response once the source of the 
stress has been eliminated. 
In mammals, the hypothalamo-pituitary-adrenal (HPA) axis is an important 
component of an organism's adaptive response to stress. Neurons involved in the 
initiation of this response synthesize corticotropin-releasing hormone (CRH). These 
neurons are mainly located in the parvocellular region of the paraventricular nucleus 
(PVN) of the hypothalamus. These neurons project to the median eminence where 
they secrete CRH into the hypophysial portal vasculature. CRH stimulates 
corticotrophs of the anterior pituitary to secrete adrenocorticotropic hormone (ACTH) 
into the peripheral circulation. ACTH then induces the secretion of corticosterone 
(CORT) from the adrenal cortex. During stressful events, corticosteroids act to 
preserve the integrity of the organism by altering several physiological parameters. 
For example, CORT increases glucose mobilization in order to provide the animal 
with the necessary energy to contend with the stressor. 
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Gonadal hormones are also known to influence HPA activity. A sex 
difference in basal CORT titers and .. in the CORT response to stress has been 
demonstrated (Kitay, 1961). Females have higher basal CORT levels and enhanced 
CORT responses to stress compared to males. The greater secretion in females is 
believed to be the result of estrogen acting to enhance HPA activity (Kitay, 1963; 
Viau and Meaney, 1991a; Burgess and Handa, 1992). Conversely, in males 
androgens may inhibit HPA activity (Critchlow et al., 1963; Gaskin and Kitay, 1971; 
Handa et al., 1994; Viau and Meaney, 199lb). Previous studies have shown that 
prepuberal gonadectomy of the male rat and hamster leads to enhanced levels of 
CORT which correlate with increases in ACTH bioactivity (Critchlow et al., 1963; 
Gaskin and Kitay, 1971). In gonadectomized male rats, the CORT and ACTH 
responses to foot shock or open field stressors are enhanced compared to intact 
animals (Handa et al., 1994). Furthermore, treatment of gonadectomized rats with 
testosterone or the non-aromatizable androgen, dihydrotestosterone (DHT), normalizes 
post-stress plasma CORT and ACTH levels. These data provide further evidence that 
the sex difference in HPA activity arises as a result of the circulating gonadal steroid 
environment. 
Several possible mechanisms could explain androgen's inhibition of HP A 
activity. Androgens could be inhibiting synthesis and/or secretion of hypothalamic 
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CRH (or other corticotropin-releasing factors such as arginine vasopressin, A VP). 
Alternatively, androgens may influence the negative feedback response of the HP A 
axis. However, this is not supported by evidence that gonadectomy of male rats does 
not alter the concentration or affinity of type I or type II CORT receptors in the 
hippocampus or hypothalamus (Handa et al., 1994). Furthermore, anterior pituitary 
responsiveness to CRH is not altered following gonadectomy of male rats (Handa et 
al., 1994). The possibility remains that androgens could be influencing hypothalamic 
CRH synthesis, storage, or secretion. 
It is important to characterize the effect(s) of gonadal hormones on the stress 
response. Dysfunction of the stress response is believed to lead to adjustment 
disorders such as depression and panic disorder. These disorders occur much more 
often in females than in males (Weissman and Klerman, 1977; Katschnig and 
Amering, 1990). While it is clear that estrogen may play an important role in 
predisposing a female to such disorders, it is equally as important to determine what 
role androgens may play in protecting a male from dysfunction of the stress response. 
Thus, this dissertation tested the hypothesis that in the male rat, circulating 
androaens modulate the neuronal circuitry responsible for mediatin& 
neuroendocrine and behavioral responses to stressful stimuli. This hypothesis was 
tested in two parts. First, the effect of circulating gonadal androgens on the HPA 
axis was examined, and secondly, the effect of circulating androgens on other 
neuroendocrine and behavioral responses to stress was evaluated. 
Four experiments were conducted to test this general hypothesis. The. first 
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experiment tested the hypothesis that androgens affect the HPA axis by reducing 
hypothalamic CRH levels. Thus, the first experiment examined the effect of 
gonadectomy and the non-aromatizable androgen, DHT, on hypothalamic CRH 
content and CRH-immunoreactive (IR) cell numbers within the PVN of male rats. 
The second experiment was performed to test the hypothesis that the influence of 
androgens on CRH content and CRH immunoreactivity in the hypothalamus are a 
consequence of changes in CRH gene expression as determined by measuring steady 
state levels of CRH mRNA. CRH mRNA levels in the PVN of intact, 
gonadectomized, and gonadectomized, DHT-treated animals were evaluated using in 
situ hybridization histochemistry (ISHH). The third experiment tested the hypothesis 
that androgens regulate CRH by acting directly within CRH containing cells of the 
PVN. The regulation of cellular processes by androgens requires the presence of the 
androgen receptor (AR) which acts as a ligand-responsive transcription factor. In 
order for androgens to directly regulate hypothalamic CRH, AR must be expressed 
within CRH containing cells of the PVN. Therefore, this experiment tested for the 
presence of AR immunoreactivity within CRH neurons in the PVN of male rats. The 
purpose of the final study was to test the hypothesis that circulating androgens 
influence neuroendocrine, autonomic, and behavioral responses to a psychological 
stressor. The effects of conditioned stress were examined in male rats that were 
intact, gonadectomized, or gonadectomized and treated with DHT. The effects of 
gonadal androgens on the stress-induced increases in plasma corticosterone, ACTH, 
prolactin, renin concentration, and renin activity were examined. In addition, this 
experiment examined the influence of androgens on the stress-induced changes in 
defecation and several behavioral parameters. 
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CHAPTERil 
REVIEW OF RELATED LITERATURE 
The "Stress Response" 
The terms "stress" and "homeostasis" were coined to describe very basic yet 
significant concepts of interaction between an organism and its environment. The 
concept of "homeostasis" was described by Cannon (1939) as a closed system of 
processes which defend the steady state against environmental stimuli that tend to 
disturb the balance. Selye (1950) observed that the body reacts to any nonspecific 
noxious agent or tissue damage with the same syndrome: hypertrophy of the adrenal, 
atrophy of the thymus, and development of gastric ulcers. He thus introduced the 
word "stress" to describe the state of the organism during the response to the noxious 
or threatening stimuli. More recently, the term "stress" has been used to refer to any 
perturbations of homeostasis and may be physiological or psychological in nature. 
In mammals, most physiological systems are affected in some way by stressful 
stimuli. The endocrine system, the autonomic system, and the immune system are all 
sensitive to such environmental changes. Stressful stimuli elicit increases in plasma 
levels of several hormones including corticosterone, prolactin, and oxytocin. 
Autonomic outputs evoke changes in the cardiovascular, respiratory, and other 
visceral systems. Changes in immune function include a suppression of T lymphocyte 
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mitogen responsiveness (Cunnick et al., 1991). All of these changes serve to 
preserve the integrity of the organism by increasing the readiness and execution of 
behaviors. This will ultimately enhance the probability of survival of the organism 
and eliminate the source of the stress. In addition, these physiological reactions 
ensure the termination of the stress response once the source of the stress has been 
eliminated. Thus, the "stress response" is an integral part of an adaptive biological 
system. 
The Hypothalamo-Pituitary-Adrenal Axis 
The hypothalamo-pituitary-adrenal (HPA) axis is a major component of the 
stress response (see Figure 1). Parvocellular neurosecretory neurons located in the 
paraventricular nucleus of the hypothalamus (PVN) synthesize a neuropeptide 
hormone, corticotropin-releasing hormone (CRH). These neurons project to the 
median eminence and terminate around the primary capillaries of the hypophysial 
portal circulation. The hypothalamus secretes CRH (and other corticotropin-releasing 
factors) into the hypophysial portal vasculature (Plotsky and Vale, 1984). 
Corticotropin-releasing hormone is the primary stimulus causing corticotrophs of the 
anterior pituitary to synthesize and secrete adrenocorticotropic hormone (ACTH) into 
the peripheral circulation (Rivier et al., 1982). Subsequently, ACTH stimulates the 
cells of the zona fasciculata to synthesize and secrete glucocorticoids (predominantly 
corticosterone, CORT, in rats and cortisol in humans; Makara, 1985; Baxter 1986). 
The activity of the HP A axis is influenced by both a circadian pacemaker and 
7 
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~ 
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+ 
PHYSIOLOGICAL EFFECTS 
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Figure 1. The hypothalamo-pituitary-adrenal (HPA) axis. In response to stress, 
corticotropin-releasing hormone (CRH) is secreted from the hypothalamus. CRH 
stimulates the anterior pituitary to secrete adrenocorticotropic hormone (ACTH) which 
subsequently stimulates the release of corticosterone (CORT) from the adrenal cortex. 
In addition to its systemic effects, CORT feeds back on the hippocampus, 
hypothalamus, and pituitary to bring CRH, ACTH, and CORT secretion back to 
baseline levels. 
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environmental stimuli. Plasma CORT levels exhibit a diurnal rhythm with peak 
circulating CORT titers at the onset of the animal's active period (Dallman et al., 
1987). In addition to the circadian fluctuations, HPA activity increases rapidly in 
response to stressful stimuli. The HP A response to environmental perturbation 
corresponds with the circadian rhythm of the axis in that the response is greatest in 
the morning when plasma CORT titers are at their circadial nadir (Bradbury et al., 
1991). During stress, corticosteroids feedback on the hippocampus, hypothalamus, 
and pituitary to bring CRH, ACTH, and adrenal steroid secretion back to basal levels 
(Kim and Kim, 1961; Jingami et al., 1985; Sapolsky et al.,1990). 
The role of circulating CORT during stress is believed to be protective in 
nature. Corticosteroids dampen physiological responses involving immunity, 
inflammation, water resorption, and glucose utiliz.ation (for rev. see Munck et al., 
1984; Axelrod and Reisine, 1984). The exposure to a noxious or threatening stimulus 
induces defense reactions such as inflammation following tissue damage. These 
responses may become detrimental if they are not terminated once the threatening 
stimulus has disappeared. It has been suggested that during stress, glucocorticoids 
inhibit the synthesis and release of several intracellular mediators of these defense 
reactions (Munck et al., 1984). Thus, corticosteroids act to prevent an overreaction 
to stress. In addition, glucocorticoids increase the synthesis of enzymes involved in 
gluconeogenesis in hepatocytes (Weber et al., 1955; Weber et al., 1964). This serves 
to increase the available energy such that the organism is better equipped to contend 
with or escape from a threatening stimulus. 
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In addition to CORT's effects on peripheral physiology, CORT also has 
profound effects upon the central nervous system. Adrenalectomy and corticosterone 
treatment have been shown to alter catecholaminergic, monoaminergic, peptidergic, 
and amino acid neurotransmitter systems (for rev. see McEwen et al., 1986). For 
example, corticosterone treatment increases dopamine turnover and release (Versteeg 
et al., 1983; Imperato et al., 1989) and decreases hippocampal norepinepherine-
stimulated cAMP production (Harrelson and McEwen, 1987). The effects of CORT 
on these neurotransmitter systems may be involved in the regulation of mood, 
perception, attention and learning (McEwen et al., 1986). 
Although glucocorticoids can serve a protective function, chronically high 
levels of circulating CORT can be detrimental. Chronically elevated plasma CORT 
can lead to steroid diabetes, hypertension, osteoporosis, immunosuppression, neuronal 
loss, impaired reproductive function, and disturbances in mood and cognitive function 
(Seyle and Tuchweber, 1976; Munck et al., 1984; Sapolsky et al., 1985; McEwen et 
al., 1986). Since these are all symptoms of aging, it has been suggested that 
chronically elevated CORT titers may be related to the aging process and age-related 
neuropathology (Landfield et al., 1978; Landfield et al., 1981; Sapolsky et al., 1986). 
Corticotropin-Releasing Hormone (CRH) and Factors (CRFs) 
Over a decade ago, Vale and colleagues (1981) sequenced and characterized 
CRH, the 41-amino acid peptide that serves as the major physiological stimulus for 
adenohypophysial ACTH secretion. The evidence indicating that CRH induces 
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adenOhYJ>OPhysial CRH secretion is extensive. CRH has been shown to stimulate the 
release of ACTH both in vitro (Vale et al., 1983a) and in vivo (Rivier et al., 1982). 
Stimulation of ACTH release by endogenous CRH is attenuated by anti-CRH 
antibodies (Rivier et al., 1984a; Van Oers et al., 1989). Also, administration of 
CRH antisera nearly abolishes the pituitary and adrenal responses to a variety of 
stressors (Rivier and Vale, 1983; Ono et al., 1985). In addition to increasing 
secretion of ACTH, CRH increases the synthesis and release of other 
adenohypophysial products of the ACTH precursor peptide, proopiomelanocortin 
(POMC; Rivier and Plotsky, 1986; Vale et al., 1983b) and the level of POMC 
mRNA (Bruhn et al., 1984; Dallman et al., 1985) in corticotroph cells of the anterior 
pituitary. 
Several other hypothalamic substances including arginine vasopressin, (A VP; 
Gillies et al., 1982; Rivier et al., 1984b; Giguere and Labrie, 1982; Rivier and Vale 
1983; Antoni et al., 1983; Vale et al., 1983a), oxytocin (Antoni et al., 1983; Vale et 
al., 1983a), and catecholamines (Vale and Rivier, 1977) synergize with CRH in its 
effects on adenohypophysial ACTH release. These substances have been proposed to 
be "CRFs". Interactions between.these CRFs appear to be physiologically important 
since the secretion of each CRF is stimulus specific (Plotsky et al., 1985a; Plotsky et 
al., 1985b). For example, during insulin-induced hypoglycemia increases in plasma 
ACTH levels have been shown to accompany increases in A VP, but not CRH or 
catecholamines, in the portal blood (Plotsky et al., 1985a). 
Several laboratories have demonstrated that neurohypophysial A VP potentiates 
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the effect of CRH on pituitary corticotrophs in both rats (Giguere and Labrie, 1982; 
Rivier and Vale, 1985a; Graf et al., 1985) and humans (Orth et al., 1985). A VP acts 
throUgh its receptor subtype, Vl, (Rivier et al., 1984b) to potentiate CRH-stimulated 
cAMP accumulation (Giguere and Labrie, 1982). However, it is currently thought 
that CRH is the only hypothalamic factor capable of inducing POMC gene expression 
(Levin et al., 1989). A VP may potentiate CRH action by increasing CRH receptors 
on the corticotroph cell surface (Madsen et al. , 1991; Jia et al. , 1991). A VP may 
accomplish this through its action on a functionally distinct population of corticotrophs 
which does not contain CRH receptors (Schwartz and Vale, 1988; Jia et al., 1991). 
In the rat, oxytocin amplifies the ACTH response to CRH much in the same 
way as A VP does (Antoni et al., 1983; Vale et al., 1983a). The effects of oxytocin 
and AVP on ACTH secretion are not additive (Gibbs et al., 1984). It is therefore 
likely that these neuropeptides act via the same intracellular pathways. Although 
oxytocin has not been shown to influence plasma ACTH levels in humans (Lewis and 
Sherman, 1985), oxytocin appears to be an important CRF in the rat. The levels of 
oxytocin in the hypophysial portal blood of the rat are 50-100 times higher than the 
concentration in peripheral blood (Gibbs, 1985; Horn et al., 1985). The source of 
this hypophysial portal oxytocin is the axons of magnocellular neurons of the 
supraoptic and accessory nuclei which are passing through the median eminence 
(Antoni et al., 1986). 
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The CRH Gene 
The gene encoding the CRH prohormone has been cloned and sequenced in 
several species (Furutani et al., 1983; Shibahara et al., 1983; Jingami et al., 1985; 
Thompson et al., 1987). The genes encoding rat and human CRH precursors are 
highly homologous and are comprised of two exons separated by an intervening intron 
(see Figure 2; Jingami et al., 1985; Thompson et al., 1987). The nucleotide 
sequence encoding the entire CRH prohormone is located on the second exon while 
the first exon encodes most of the 5 '-untranslated regions of the mRNA. Comparison 
of the human and rat gene reveals a high degree of homology not only in the peptide 
encoding region, but also in the 5'-flanking sequence. The 5'-flanking region is 
likely to contain DNA sequence elements responsible for tissue specific expression as 
well as second messenger and steroid regulation of gene expression. For example, a 
cAMP-responsive element has been localized to a 59-base pair region located between 
238 and 180 base pairs 5' to the CRH cap site (Seasholtz et al., 1988). 
Induction of immediate early genes such as c-fos may be involved in CRH 
gene expression. Induction of c-Fos immunoreactivity has been observed in CRH-
immunoreactive (IR) parvocellular neurons of the PVN following various stressors 
(Ceccatelli et al., 1989a) as well as following adrenalectomy (Jacobson et al., 1990). 
Recently, a temporal correlation was reported in which the enhanced expression of 
CRH mRNA in the PVN following immobilization stress was preceded by the 
induction of c-fos mRNA (lmaki et al., 1992). However, this is contradicted by a 
study demonstrating that CRH heterogeneous nuclear RNA and c-fos mRNA rise 
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intron CRH 
Rat CRH Gene 
CRH 
RatCRHmRNA 
jcRHj 
Rat CRH Protein Precursor 
Figure 2. Structural organization of the rat corticotropin-releasing hormone (CRH) 
gene, mRNA (1400 nucleotides), and protein precursor (187 amino acids). The exons 
of the gene are shown as blocks. The intron, 5'- and 3'-flanking sequences are 
shown as lines. The 5'- and 3'-untranslated regions are shaded. The cAMP-
responsive element (CRE) is indicated. The location of the CRH peptide is indicated 
by CRH (adapted from Thompson et al., 1987). 
concomitantly following blockade of corticosterone synthesis with metyrapone 
(Herman et al., 1992). 
Localization of CRH Neurons 
The PVN is composed of a cluster of neurons that lie dorsally along the third 
ventricle (see Figure 3). The PVN contains at least three functionally and 
anatomically distinct groups of neurons (see Figure 4; for rev. see Swanson, _1987). 
PVN 
Figure 3. The paraventricular nucleus of the hypothalamus (Interaural 7 .20 mm, 
Bregma -1.80 mm; adapted from Paxinos and Watson, 1986). 
The parvocellular neurosecretory group consists of neurons that project to the 
neurohemal zone of the median eminence, where they release hormones into the 
hypophysial portal circulation. These cells are found in the dorsal medial 
parvocellular and periventricular subdivisions of the PVN. The magnocellular 
neurosecretory group consists of large neurons whose axons project to the posterior 
pituitary where they release vasopressin and oxytocin into the general circulation. 
These neurons are concentrated in the anterior, medial, and posterior magnocellular 
subdivisions of the PVN. The third group of neurons are localized to the dorsal, 
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ventral medial and lateral parvocellular subdivisions of the PVN. These neurons give 
rise to descending projections to other areas of the hypothalamus, the brainstem and 
the spinal cord. These neurons are believed to influence the autonomic nervous 
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Figure 4. The subdivisions of the paraventricular nucleus of the hypothalamus 
(PVN). Frontal sections are arranged from rostral (A) to caudal (F). AHA, anterior 
hypothalamic area; am, anterior magnocellular part of the PVN; ap, anterior 
parvocellular part of the PVN; BNSTP, bed nucleus of the stria terminalis (preoptic 
part); dp, dorsal parvocellular part of the PVN; f, fornix; lp, lateral parvocellular part 
of the PVN; met, medial cortico-hypothalamic tract; mp, medial parvocellular part of 
the PVN; pm, posterior magnocellular part of the PVN; pv, periventricular part of the 
PVN; ZI, zona incerta (adapted from Swanson, 1987). 
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system, the output of the central gray and reticular formation, and the central relay of 
visceral and nociceptive information. 
CRH containing neurons are found in all 8 divisions of the PVN, however 
most are found in the dorsal medial parvocellular part (for rev. see Sawchenko and 
Swanson, 1990). The axons of these cells project laterally around the fornix and end 
in the neurohemal zone of the median eminence where CRH is released into the 
hypophysial portal blood. 
CRH neurons are found in many other areas of the central nervous system. 
Other hypothalamic sites in which CRH-IR cells have been observed include the 
arcuate, periventricular, premammillary, preoptic, supraoptic, and suprachiasmatic 
nuclei (for rev. see Sawchenko and Swanson, 1990). The majority of the projection 
fields of these CRH-IR cells are unknown. Extrahypothalamic brain areas containing 
CRH neurons include a dense cluster of CRH neurons within the central nucleus of 
the amygdala (CeA) and in the bed nucleus of the stria terminalis (BNST; Swanson 
et al., 1983; Moga and Gray, 1985; Gray and Magnuson, 1987). Although the 
function of these cells has not been fully characterized, these neurons may serve to 
coordinate endocrine, autonomic, and behavioral responses to stress (for rev. see 
Menughi et al., 1993). 
Localiution of CRH mRNA coincides with immunocytochemical data of 
peptide locali7.at.ion. Using in situ hybridiution histochemistry (ISHH), CRH mRNA 
was observed in both the parvocellular and magnocellular regions of the PVN as well 
as in the supraoptic nucleus of the hypothalamus (Young et al., 1986a; Lightman and 
young, 1987). Additionally, Northern blot analysis has revealed CRH mRNA in 
RNA extracted from the PVN, amygdala, BNST, and supraoptic nucleus (Beyer et 
al., 1988). 
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Other neuropeptides including A VP are localized within various subsets of the 
parvocellular PVN CRH neurons. Furthermore, adrenalectomy induces expression of 
A VP in the majority of CRH cells in the PVN (Roth, et al., 1982; Sawchenko, et al., 
1984), and the ratio of A VP: CRH release from the median eminence in vitro 
increases from 2: 1 in the intact rat to 8: 1 in adrenalectomized animals (Holmes et al., 
1986). This could be important since AVP is believed to potentiate the effect of CRH 
on ACTH secretion. In addition, oxytocin (Sawchenko et al., 1984), neurotensin 
(Ceccatelli et al., 1989b), dynorphin (Roth et al., 1983), enkephalin (Ceccatelli et al., 
1989b; Hokfelt et al., 1983), and enkephalin mRNA (Pretel and Piekut, 1990) have 
been localized within CRH neurons in the PVN. The function of these colocalized 
peptides is unknown, but one peptide may influence the action of the other at the level 
of the anterior pituitary. 
Neuroanatomical Inputs to the PVN 
The neuroanatomical inputs to the PVN arise from both extrahypothalamic and 
intrahypothalamic sources (for rev. see Swanson and Sawchenko, 1983; Swanson, 
1987; Palkovits, 1987). Extrahypothalamic inputs are derived from three general 
systems: the limbic system, the lower brain stem, and the circumventricular organs 
(see Figure 5). Limbic system structures which influence the PVN include the 
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hipp<>CaIIlPUS (subiculum), the amygdala, and the septum. Most of these structures do 
not send direct pathways to the PVN but rather relay through the septum, the bed 
nucleus of the stria terminalis, or various hypothalamic nuclei (Sawchenko and 
Swanson, 1983). 
Lower brainstem inputs to the PVN originate from the raphe nuclei, the locus 
coeruleus, the parabrachial nucleus, the nucleus of the solitary tract, and the reticular 
formation. Cells in the lateral reticular nucleus (Al-Cl cells in the ventrolateral 
medulla), the medial part of the nucleus of the solitary tract (A2-C2 cells in the 
dorsomedial medulla), and the locus coeruleus (A6 cell group) give rise to the 
majority of the noradrenergic and adrenergic innervation of the PVN (Palkovits et al. , 
1980a; Palkovits et al., 1980b; Sawchenko and Swanson, 1982; Kiss et al., 1983). 
The axons of these cells ascend via a periventricular route or via the ventral tegmental 
bundle-medial forebrain bundle system or to the PVN. Serotoninergic innervation of 
the PVN originates from the median and dorsal raphe nuclei (Sawchenko et al., 1983; 
Palkovits et al., 1977). 
Circumventricular organ innervation of the PVN arises from the subfomical 
organ and the organum vasculosum lamina terminalis. The pathway from the 
subfomical organ to the PVN contains angiotensin TI immunoreactivity (Lind et al. , 
1984) and is activated by hemorrhage (Abdelaal et al., 1974; Mangiapani and 
Simpson, 1980; Knepel et al., 1982; Lind et al., 1983). Thus, subfomical organ 
innervation of the PVN is likely to be involved in the release of CRH, vasopressin, 
and oxytocin during hypovolemia (Swanson, 1987). 
IX,X 
Figure 5. Summary of major neural inputs to the paraventricular nucleus of the 
hypothalamus (PVN). Limbic system inputs include projections from the 
hippocampus and amygdala. Al, Al-Cl cells in the ventrolateral medulla; BNST, 
bed nucleus of the stria terminalis; HYP, various hypothalamic nuclei; IX, 
glossopharyngeal nerve; NTS, nucleus of the solitary tract; PBN, parabrachial 
nucleus; R, raphe nuclei; SEP, septum; SFO, subfornical organ; X, vagus nerve 
(adapted from Swanson, 1987). 
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Intrahypothalamic inputs to the PVN arise from almost all of the hypothalamic 
and preoptic nuclei (Swanson and Cowan, 1975; Swanson, 1976; Saper et al., 1976; 
Saper et al., 1978; Saper et al., 1979; Silverman et al., 1981). Currently, most of 
this innervation has not been neurochemically characterized. Those inputs that have 
been characterized are peptidergic, using transmitters such as angiotensin II and 
neuropeptide Y (Bai et al., 1985). Using electron microscopic immunocytochemistry, · 
synaptic specializations between magnocellular neural processes and CRH-IR 
perikarya have been observed (Leranth et al., 1983). Thus, it is likely that 
magnocellular neurons within the PVN (probably containing vasopressin or o~ytocin) 
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also innervate CRH neurons. 
Signals indicating the existence of physical and psychological stress reach the 
pVN via multiple neural pathways. Anatomical and physiological evidence suggest 
that somatosensory and viscerosensory information reaches the PVN via multi-
synaptic neural pathways (Palkovits, 1987; Swanson, 1987). This information reaches 
the medullary and pontine reticular formation and biogenic amine containing cells 
groups. Projections from these cells ascend to the PVN via the ventral tegmental 
tract and medial forebrain bundle. For example, the nucleus of the solitary tract 
receives visceral information from the vagus and glossopharyngeal cranial nerves. 
These signals are then conveyed to the PVN. This example is probably the most 
direct route to the PVN for viscerosensory information. In contrast, psychogenic 
stress probably requires neural processing in the cerebral cortex (Swanson, 1987). 
This cognitive information is then carried to limbic regions such as the hippocampus 
and amygdala. The hippocampus and amygdala then relay the signals to the PVN. 
Although direct innervation of the PVN from the amygdala has been demonstrated 
(Gray et al., 1989) both the hippocampus and amygdala send indirect connections to 
the PVN via the septum and bed nucleus of the stria terminalis (Swanson, 1987; 
Cullinan et al., 1993). 
Neurotransmitters Influencing CRH Secretion 
Several neurotransmitter systems are believed to influence the secretion of 
CRH from parvocellular PVN neurons (for rev. see Tsagarakis and Grossman, 1990; 
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Table 1. Neurotransmitters that control hypothalamic CRH release. 
STIMULATORY INHIBITORY 
Acetylcholine GABA 
Norepinepherine Opioids 
Serotonin Substance P 
Angiotensin II Atrial Natriuretic Peptide 
Neuropeptide Y Vasopressin 
Activin 
Whitnall, 1993). In general, acetylcholine, catecholamines, serotonin, and some 
neuropeptides such as angiotensin II and neuropeptide Y are believed to have a 
stimulatory effect on hypothalamic CRH secretion. In contrast, gamma-aminobutyric 
acid (GABA), endogenous opioids, and neuropeptides such as substance Pare thought 
to inhibit secretion of CRH into the hypophysial portal blood. These neurotransmitter 
effects on hypothalamic CRH release are summarized in Table 1. 
A great deal of evidence supports a stimulatory effect of acetylcholine on 
ACTH secretion. Intracerebroventricular injection or median eminence implantation 
of the cholinergic agonist, carbachol, yielded an increase in plasma CORT levels 
(Krieger and Krieger, 1970; Abe and Hiroshige, 1974). Furthermore, implantation of 
the cholinergic antagonist atropine rostral to the PVN was found to decrease the 
ACTH responses to surgical and ether stress (Hedge and Smelik, 1968; Hedge and De 
Wied, 1971). In vitro studies using hypothalamic explants indicated that 
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administration of acetylcholine increased CRH bioactivity and CRH as measured by 
radioimmunoassay (Hillhouse et al., 1975; Buckingham and Hodges, 1979; Suda et 
al., 1987; Tsagarakis et al., 1988; Calogero et al., 1988a). In vivo, administration of 
acetylcholine resulted in an increase in hypophysial portal CRH in anesthetized rats 
(Plotsky et al., 1987). Both nicotinic and muscarinic receptors may be involved in 
this response although the muscarinic response is probably the dominant one 
(Tsagarakis et al., 1988). This is consistent with the distribution of cholinergic 
receptors as the muscarinic receptor is more predominant in the hypothalamus (Dolly 
and Barnard, 1984). 
The effect of catecholamines on hypothalamic CRH secretion is somewhat 
controversial (for rev. see Plotsky et al., 1989; Whitnall, 1993). However, the 
strongest evidence indicates that catecholamines stimulate HPA activity. 
Administration of norepinepherine to rats under basal conditions increases circulating 
ACTH (Szafarcayk et al., 1987; Plotsky et al., 1987; Guillaume et al., 1987). 
Electrical or chemical activation of catecholaminergic afferent pathways to the 
hypothalamus yields increases in CRH, ACTH, and CORT secretion while blockade 
or destruction of these pathways decreases HPA activity (Plotsky et al., 1989). In 
vitro, norepinepherine stimulation of CRH secretion is blocked by /3-adrenergic 
antagonists (Tsagarakis et al., 1988). This implicates the /3-adrenergic receptor in the 
stimulatory effect of catecholamines on CRH secretion. Norepinepherine can also 
increase adrenocortical secretion through an ai-adrenergic receptor-mediated event 
(Al-Damluji et al., 1987; Plotsky, 1987; Calogero et al., 1988b; Al-Damluji et al., 
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l990). However, this response is thought to be the result of an increased secretion of 
vasopressin (a potent CRF) from the hypothalamus rather than CRH (Al-Damluji et 
al., 1990). Activation of a 2-adrenergic receptors results in an inhibition of CRH 
secretion (Al-Damluji, 1988). This is believed to be the result of presynaptic binding 
of a 2-receptor agonists causing a decrease in catecholamine release (Smythe et al. , 
1983). 
Several studies have demonstrated that activation of central 5HT1 and 5HT2 
serotonin receptors enhances HPA activity (Szafarczyk et al., 1979; Bagdy et al., 
1989; Golden et al., 1989; Alper, 1990; Di Sciullo et al., 1990; Fuller, 1990; 
Gartside and Cowen, 1990; Matsuda et al., 1990; Bagdy et al., 1991). In vitro 
studies report increases in bioassayable CRF (Jones and Hillhouse, 1977; Buckingham 
and Hodges, 1979) and in CRH (Nakagami et al., 1986; Calogero et al., 1989; 
Hillhouse and Milton, 1989; Spinedi and Gaillard, 1991) following administration of 
serotonin to hypothalamic explants or long term hypothalamic cultures (Nakagami et 
al., 1986; Calogero et al., 1989). In addition, serotonin has been shown to increase 
CRH secretion in vivo (Gibbs and Vale, 1983). Thus, strong evidence exists 
implicating a stimulatory effect of serotonin on HP A function at the level of the 
hypothalamus. 
In vivo studies demonstrate that GABA and GABA receptor agonists inhibit 
and GABA receptor antagonists enhance stress-induced HP A activity (Makara and 
Stark, 1974). GABA receptor antagonists have also been shown to stimulate 
adrenocortical secretion under basal conditions (Makara and Stark, 1974). Similarly, 
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intraeerebroventricular injection of GABA and GABA receptor agonists increased 
hypothalamic CRH secretion (Makara and Stark, 1974). Furthermore, stimulated 
release of both bioassayable corticotropin-releasing activity and CRH (as measured by 
radioimmunoassay) were inhibited by GABA in vitro (Jones and Hillhouse, 1977; 
Buckingham and Hodges, 1979; Calogero et al., 1988c; Tsagarakis et al., 1990a). 
There is a dense network of GABA-ergic fibers surrounding the PVN (Meister et al. , 
1988). Also, GABA is co-stored and co-released from CRH neurons and may act on 
presynaptic receptors in the median eminence (Meister et al. , 1988). It is therefore 
likely that GABA is an important inhibitor of hypothalamic CRH release. 
Endogenous opioids are generally believed to be inhibitory with respect to 
their effects on hypothalamic CRH secretion. In vitro, several opioids have been 
shown to decrease CRH secretion stimulated by neurotransmitters or depolarizing 
agents (Tsagarakis et al., 1989a; Tsagarakis et al., 1990b). Furthermore, 
administration of opioid receptor antagonists significantly increases basal CRH 
secretion. In anesthetized rats, opioid administration decreases hypophysial portal 
CRH and nitroprusside-induced CRH release (Plotsky, 1986). Thus, endogenous 
opioids may serve to maintain an inhibitory tone upon CRH release. This is believed 
to involve kappa- and possibly mu-, but not delta-opioid receptors (Tsagarakis and 
Grossman, 1990; Whitnall, 1993). 
Several neuropeptides have been demonstrated to influence HP A activity and 
CRH secretion. In vivo and in vitro studies suggest that angiotensin II (Plotsky et al. , 
1988), neuropeptide Y (Wahlestedt et al., 1987; Haas and George, 1987; Tsagarakis 
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et al., 1989b), and activin (Plotsky et al., 1991) are stimulatory in this respect while 
atrial natriuretic peptide (Takao et al., 1988; Ibanez-Santos et al., 1990), substance P 
(Chowdrey et al., 1990; Faria et al., 1991), and vasopressin (Plotsky et al., 1984) 
are inhibitory. The inhibition of HP A activity by vasopressin appears paradoxical 
since vasopressin also has corticotropin-releasing activity. However, this may be one 
mechanism by which the system is kept in check. 
Effects of Stress/Feedback on CRH Neurons 
Stress and Glucocorticoids 
Following stress, glucocorticoids act at the levels of the pituitary, 
hypothalamus, and extrahypothalamic loci within the brain to return HPA activity to 
homeostatic levels. This feedback inhibition has been a topic of intense research and 
has been extensively reviewed (Keller-Wood and Dallman, 1984; Jones and Gillham, 
1988). This review will focus only on glucocorticoid feedback inhibition at (or 
above) the level of the hypothalamus. The data presented in this section are 
summarized in Table 2. 
Corticosteroid feedback on CRH secretion has been demonstrated by the 
examination of the effects of adrenalectomy and/or the treatment with exogenous 
glucocorticoids on basal and stress-induced CRH activity. Adrenalectomy-induced 
increases in CRH and A VP immunoreactivity in parvocellular neurosecretory neurons 
are inhibited by systemic glucocorticoid replacement (Sawchenko, 1987a; Itoi et al., 
1987). Dexamethasone blocks increases in hypophysial portal vessel concentrations of 
CRH-induced by hemorrhage stress (Plotsky and Vale, 1984), and plasma CORT 
levels between 80 and 120 ng/ml suppress hypotensive stress-induced increases in 
CRH release (Plotsky et al., 1986). Conversely, adrenalectomy increases CRH and 
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A VP concentrations in hypophysial portal plasma 3 weeks following surgery (Fink et 
al., 1988). Pharmacological adrenalectomy using metyrapone or aminoglutathimide 
leads to a decrease in secretion of CRH and AVP in the initial 12-24 hours but an 
increase in CRH release by 72 hours (Plotsky and Sawchenko, 1987). The decrease 
probably reflects an initial depletion of releasable CRH pools while the subsequent 
increase represents the removal of inhibition by adrenal glucocorticoids. 
Furthermore, secretion of CRH from cultured hypothalami can be inhibited by CRH, 
ACTH, and dexamethasone (Calogero et al., 1988d; Suda et al., 1986). These 
studies demonstrate a hypothalamic locus for negative feedback regulation of the HPA 
axis but do not, however, indicate whether changes in synthesis, storage, or release of 
hypothalamic CRF's explain this phenomenon. 
To further characterize the role of the hypothalamus in the negative feedback 
of the HPA axis, several investigators have studied the effects of stress, 
adrenalectomy, and glucocorticoids on CRH and A VP gene expression. CRH mRNA 
(Young et al., 1986a; Kovacs and Mezey, 1987; Lightman and Young, 1989; Beyer 
et al., 1988; Imaki et al., 1991; Almeida et al., 1992) and AVP mRNA (Young et 
al., 1986b) increase in the parvocellular PVN following adrenalectomy. These 
increases are abolished by glucocorticoid replacement (Lightman and Young, 1989; 
Kovacs and Mezey 1987; Beyer et al., 1988; Imaki et al., 1991). This response to 
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Table 2. Effect of stress, adrenalectomy and glucocorticoid treatment on 
hypothalamic corticotropin-releasing hormone (CRH) and 
vasopressin (A VP). 
TREATMENT EFFECT MEASUREMENT REFERENCES 
Adrenalectomy increases CRH-IR and A VP-IR Sawchenko, 1987; Itoi et al., 
in parvocellular PVN 1987 
CRH mRNA and Young et al., 1986a; Kovacs 
AVPrnRNA and Mezey, 1987; Lightman 
Glucocorticoid decreases parvocellular PVN and Young, 1989; 
replacement Beyer et al., 1988; Imaki et 
al., 1991; Almeida et al., 
1992; Young et al., 1986b 
Hemorrhage stress increases Hypophysial portal Plotsky and Vale, 1984 
CRH 
Dexamethasone decreases 
Hypotensive stress mcreases Plotsky et al., 1986 
Plasma corticosterone decreases 
(80-120 ng/rnl) 
Adrenalectomy mcreases Hypophysial portal Fink et al., 1988 
CRH and A VP 
Metyrapone (12-24h) decreases Plotsky and Sawchenko, 
1987 
Metyrapone (72h) increases 
CRH decreases Secretion of CRH Calogero et al., 1988; Suda et 
from cultured al., 1986 
ACTH decreases hypothalami 
Dexamethasone decreases 
Hypertonic saline increases CRH mRNA levels in Lightman and Young, 1988; 
stress PVN Lightman and Young, 1989 
+ Adrenalectomy increases 
+ Dexamethasone decreases 
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a&enaiectomy and glucocorticoid replacement appears to be specific to the 
parvocellular PVN as magnocellular AVP mRNA (Young et al., 1986b) and CRH 
mRNA in the BNST and CeA (Beyer et al., 1988) are not affected. CRH mRNA and 
A VP mRNA also increase in the medial parvocellular region of the PVN within 4 
hours of hypertonic saline stress (Lightman and Young, 1988; Lightman and Young, 
1989). This may represent an increase in synthesis of CRH to replenish CRH stores 
released during stress. Hypertonic saline stress leads to greater increases in CRH 
mRNA in the PVN in the absence of negative feedback, i.e. in adrenalectomized 
animals as compared to intacts (Lightman and Young, 1989). Furthermore, 
dexamethasone-treatment attenuates basal and stress-induced increases in CRH mRNA 
levels (Lightman and Young, 1989). Thus, changes in CRH and AVP gene 
expression may be associated with the negative feedback of the HP A axis following 
stress. 
Corticosteroid Receptors 
Adrenocorticosteroids exert their effects by binding one of two intracellular 
receptors (for rev. see DeKloet et al., 1987). These receptors have been given the 
designations type I and type II corticosteroid receptors. The two receptor subtypes 
differ from each other in their anatomical distribution, their pharmacalogical 
properties, and their function. The type I receptor, or mineralocorticoid receptor, is 
localized predominantly in the hippocampus and septum (McEwen et al., 1968; Reul 
and DeKloet, 1985; Van Eekelen et al., 1988; Arriza et al., 1988; Herman et al., 
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!989). This receptor binds with a very high affinity to CORT, aldosterone, and 
dexamethasone (Beaumont and Fanestil, 1983; Krosowski and Funder, 1983; Reul and 
oeKloet, 1985; Allen et al., 1988; Brinton and McEwen, 1988). Because of this 
high affinity binding, the mineralocorticoid receptor is functionally important when 
plasma corticosteroids are low. Thus, the mineralocorticoid receptor is believed to be 
involved in tonic and permissive functions. These include the regulation of 
exploration (Veldhuis and DeKloet, 1983), food seeking (Jhanwar-Uniyal et al., 
1986), and basal (i.e., circadian) HPA activity (Dallman et al., 1989; Ratka et al., 
1989). 
The type II receptor, or glucocorticoid receptor, is localized in glial cells and 
neurons throughout the central nervous system (Fuxe et al., 1985; Reul and DeKloet, 
1985; Reul and DeKloet, 1986; Van Eekelen, et al., 1987; Aronsson et al., 1988; 
Sarrieau et al., 1988; Van Eekelen et al., 1988; Ceccatelli et al., 1989c; Herman, et 
al., 1989; Sousa et al., 1989). The regions of highest concentration of glucocorticoid 
receptor include the hippocampus, PVN, lateral septum, central amygdala, arcuate 
nucleus, and supraoptic nucleus. The glucocorticoid receptor also binds CORT and 
dexamethasone but with lower affinity than the mineralocorticoid receptor (Krosowski 
and Funder, 1983; Reul and DeKloet, 1985; Brinton and McEwen, 1988). Because 
the glucocorticoid receptor binds CORT with a low affinity, this receptor is only 
occupied when plasma CORT levels are high. Thus, the glucocorticoid receptor is 
thought to be involved in the regulation of behavioral, neuroendocrine, and autonomic 
responses to stress and participates in the negative feedback inhibition of HP A activity 
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following stress (Reul and DeKloet, 1985). 
Neuroanatomica1 Locus of Feedback Inhibition 
There is significant evidence implicating the hippocampus, which contains both 
CORT receptor types, in the regulation of the HPA axis (for rev. see Jacobsen and 
Sapolsky, 1991). Most experiments indicate that the role of the hippocampus in this 
respect is inhibitory in nature. For example, electrical stimulation of the 
hippocampus decreases plasma CORT levels (Mandell et al., 1963; Rubin et al., 
1966), and fornix transection or hippocampectomy results in increased plasma CORT 
levels (Nakadate and DeGroot, 1963; Wilson et al., 1980). Furthermore, 
hippocampal stimulation inhibits and hippocampal lesion augments the CORT 
secretion induced by exposure to a stressor (Dupont et al., 1972, Kawakami et al., 
1968). The hippocampus is also implicated in the termination of HP A responses to 
stress in that secretion of CORT persists much longer after exposure to restraint stress 
in rats with kainate lesions of the hippocampus (Sapolsky et al., 1984a). 
In addition to the role of the hippocampus in the negative feedback response of 
glucocorticoids, the PVN remains a probable site of direct glucocorticoid action in 
this respect. Immunocytochemical studies reveal the presence of glucocorticoid 
receptors in CRH-containing neurons in the PVN (Ceccatelli et al., 1989c). 
Furthermore, unilateral implantation of dexamethasone into the PVN inhibits the 
adrenalectomy-induced increases in CRH and A VP immunoreactivity (Kovacs et al., 
1986; Sawchenko, 1987b) and in CRH mRNA (Kovacs and Mezey, 1987) on. the 
implanted side. Interestingly, these studies reported that implantation of 
dexamethasone into the hippocampus resulted in a slight decrease in the 
adrenalectomy-induced effects on CRH and A VP immunoreactivity (Kovacs et al., 
1986) while no effect was seen on CRH mRNA (Kovacs and Mezey, 1987). 
The Hypothalamo-Pituitary-Gonadal Axis 
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The hypothalamo-pituitary-gonadal axis is an essential element of reproductive 
function. A subset of hypothalamic neurons synthesize gonadotropin-releasing 
hormone (GnRH) which is also known as leutenizing hormone releasing hormone 
(LHRH). These neurons project to the median eminence where they secrete GnRH 
episodically into the hypophysial portal vasculature (for rev. see Marshall et al. , 
1992; Pfaff et al., 1994). Gonadotropin-releasing hormone stimulates gonadotroph 
cells of the anterior pituitary to synthesize and secrete leutenizing hormone (LH) and 
follicle-stimulating hormone (FSH). In the male, leutenizing hormone stimulates 
Leydig cells of the testes to produce and secrete testosterone. Testosterone is 
necessary for spermatogenesis, reproductive behavior, and the development of male 
secondary sex characteristics. In addition, testosterone feeds back on the brain and 
pituitray to reduce HPG axis activity (Petraglia et al., 1984; Bhanot and Wilkinson, 
1985; Gabriel et al., 1986; Wehrenberg et al., 1989; Kalra et al., 1990; Sahu et al., 
1990; Huang and Harlan, 1993). 
Products of the HP A axis have been shown to inhibit reproductive function. 
Several studies have demonstrated that CRH attenuates hypothalamic GnRH secretion 
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(Rivier and Vale, 1984; Rivier and Vale 1985b; Rivier et al., 1986). Furthermore, 
ACTH and corticosterone act on the hypothalamus, pituitary, and gonads to decrease 
HPG axis activity (Vreeburg et al., 1984; Kamel and Kubajak, 1987; Mann et al., 
1987). Moreover, products of the HPA axis suppress reproductive behaviors (Plas-
Rose and Aron, 1981; Sirinathsinghji et al., 1983; Armstrong, 1986; Sirinathsinghji 
et al., 1986). 
Effects of Gonadal Steroids on the HPA Axis 
Previous studies have demonstrated a significant sex difference in circulating 
CORT levels and in the CORT response to stress with females having higher levels 
than males (Kitay, 1961). Since then, several studies have focused on the role of 
estrogen in this sex difference (Kitay, 1963; Telegdy et al., 1964; Raps et al., 1971; 
Pollard et al., 1975; Ramaley, 1976; Buckingham et al., 1978; Phillips and 
Poolsanguan, 1978; Burgess and Handa, 1992). These studies demonstrate that basal 
CORT levels are decreased in ovariectomized rats as compared to ovariectomized rats 
receiving estrogen replacement (Kitay, 1963; Telegdy et al., 1964; Ramaley, 1976; 
Lesniewska et al., 1990). In addition, basal CORT as well as stress-induced CORT 
and ACTH levels vary with the estrous cycle (Raps et al., 1971; Pollard et al., 1975; 
Buckingham et al., 1978; Phillips and Poolsanguan, 1978; Viau and Meaney, 199la). 
ACTH and CORT levels are greatest on proestrous when estrogen levels are highest. 
A number of studies have suggested that estrogen influences HP A activity, at 
least in part, at the level of the PVN. Chronic estrogen treatment of ovariectomized 
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female rats significantly reduced hypothalamic CRH content as determined by 
radioimmunoassay of hypothalamic extracts (Haas and George, 1988). A subsequent 
study suggested that this decrease in hypothalamic CRH content was the result of an 
inhibition of CRH synthesis (Haas and George, 1989). CRH mRNA in the 
parvocellular PVN has also been shown to vary across the estrous cycle (Bohler et 
al., 1990). CRH mRNA is elevated on the afternoon of proestrous, at the time of the 
estrogen-induced midcycle surge of luteinizing hormone. 
Fewer studies have focused on the effects of testosterone on the HP A axis. 
Gonadectomy of the male rat and hamster leads to enhanced levels of CORT 
correlating with increases in ACTH bioactivity (Critchlow et al., 1963; Gaskin and 
Kitay, 1971). Following foot shock stress or exposure to a novel environment, 
plasma CORT and ACTH levels are higher in gonadectomized male rats as compared 
to intact animals (Handa et al., 1994). Gonadectomized rats receiving replacement 
testosterone (T) or the non-aromatizable androgen, dihydrotestosterone (DHT), have 
post-stress plasma CORT and ACTH levels similar to that seen in intact animals 
(Handa et al., 1994). These data suggest that, in contrast to the effects of estrogen, 
androgens act to inhibit the CORT and ACTH responses to stressful stimuli. 
Gonadal Regulation of A VP Expression 
Aside from the neurohypophysial neurons of the PVN that secrete A VP into 
the portal vasculature, a number of A VP-immunoreactive neuronal pathways have 
been demonstrated in the rat brain (Buijs, 1978). These AVP fibers arise from AVP-
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IR cell bodies in the PVN (Devries and Buijs, 1983; Sawchenko and Swanson, 
1982), BNST (De Vries and Buijs, 1984), medial amygdala (MeA; Caffe et al., 1987), 
and suprachiasmatic nucleus (Hoomeman and Buijs, 1982). 
A sex difference in AVP fiber density has been demonstrated. The density of 
A VP fibers in the lateral septum and lateral habenular nucleus is higher in males than 
in females (DeVries et al., 1981). Lesioning and tracing studies indicate that the 
origin of these fibers probably lies in the BNST (DeVries and Buijs, 1984). This sex 
difference is dependent on the neonatal presence of testosterone (DeVries et al., 
1983). In the adult animal, androgens appear to maintain this sex difference since 
gonadectomy of male rats has been shown to lead to a disappearance of AVP-IR cell 
bodies and A VP mRNA in the BNST and MeA without affecting A VP-IR cell bodies 
in the PVN (DeVries et al., 1985; Miller et al., 1992). Furthermore, androgen 
receptor immunoreactivity has been localized within A VP-expressing cells of the 
BNST and MeA (Zhou et al., 1994). 
Similarly, A VP fiber density in several brain regions including the MeA, 
lateral septum, and lateral habenular nucleus has been shown to decrease in the aged 
rat (Fliers et al., 1985). In the rat, plasma T levels decline with age (Kaler and 
Neaves, 1981). When plasma T levels in aged rats were restored to that of young 
animals A VP fiber density was also restored (Goudsmit et al., 1988). This evidence 
coupled with evidence that androgen and estrogen receptors are found within neurons 
of the BNST and MeA (Wood et al., 1992; Wood and Newman, 1993; Don Carlos et 
al., 1991; Tobet et al., 1993) supports a role for gonadal hormones in the regulation 
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of A VP expression in some brain regions. 
While these data demonstrate that androgens can regulate neuropeptides, 
changes in the A VP system would not explain changes in the CORT and ACTH 
responses to stress noted in the castrated male rat. DeVries, et al. (1985) report that 
castration did not affect the number of A VP-IR cell bodies in the PVN, and changes 
in AVP-IR cell bodies in other brain regions were in the wrong direction to explain 
androgen influences on the HPA response to stress. 
Mechanism of Steroid Action 
Signal Transduction 
Gonadal steroids initiate changes in cellular function via specific intracellular 
receptors which act as ligand-responsive transcription factors (for rev. see Blaustein, 
1985; Evans, 1988). The gonadal and adrenal steroid receptors have been grouped in 
a "superfamily" of intracellular receptors due to the similar function and high degree 
of sequence homology among these receptors (for rev. see Evans, 1988). This 
receptor superfamily includes receptors for vitamin D, thyroid hormone, retinoic acid, 
and the retroviral oncogene product, v-erb A. (The mechanism of steroid receptor 
action is depicted in Figure 6). 
Previously, it was believed that unoccupied steroid receptors may be localized 
in the cytoplasm and may need to be translocated into the cell's nucleus following 
ligand binding. Recent data, however, suggest that unoccupied receptors may be 
localized within the cell nuclei (Sheridan et al., 1979; King and Greene, 1984; 
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Welshons et al., 1984; Gase et al., 1989; Zhuang et al., 1992; Pekki et al., 1992). 
These unbound receptors are found complexed with two 90 kiloDalton heat shock 
protein (hsp90) molecules (Catelli et al., 1985; Sanchez et al., 1985; Mendel and 
Orti, 1988). The function of hsp90 may be related to protein folding, transport, 
and/or stabilization (Pratt, 1990). Other heat shock proteins, hsp59 and hsp70, also 
participate in this multiprotein complex (Sanchez, 1990; Muller and Renkawitz, 1991) 
although their functions are currently unknown. The inactive complex is loosely 
bound to nuclear chromatin. 
When the hormone binds to its high affinity binding site on the receptor 
molecule, hsp90 dissociates. The receptor-ligand complex can then become tightly 
bound to DNA. When bound to its ligand, an intracellular receptor alters gene 
expression of specific steroid-responsive genes. Steroid-responsive genes contain 
short (about 20 base pairs) cis-acting sequences or hormone response elements 
(HREs) that are required for hormonal activation of the gene (Govindan et al., 1982; 
Scheidereit et al., 1983; Karin et al., 1984). These HREs function in a position- and 
orientation-independent fashion as transcriptional enhancers (Chandler et al., 1983). 
Thus, transcriptional regulation depends on the binding of hormone-receptor 
complexes to HRE sites on DNA. Identification of HRE sequences reveals an 
apparent dyad symmetry implying that HREs interact with receptor dimers (Waterman 
et al., 1988; Chalepakis et al., 1990). 
Hormone-receptor coupling is also necessary for induction of the receptors 
trans-activation function (Webster et al., 1988). The ligand-receptor complex- alters 
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gene transcription by interacting with other components regulating transcription. For 
example, ligand-activated steroid receptors have been shown to interact with the factor 
which binds to a consensus sequence, the TATA box, found within many promoter 
regions (Ptashne, 1988; Ham et al., 1988). 
Steroid receptors have been shown to interact with other transcription factors 
as well (Schule et al., 1988; Strahle et al., 1988). For example, binding of the 
glucocorticoid receptor to its HRE enhances the transcription induced by the binding 
of another factor to its binding site, a CACCC-box (Schule et al., 1988). This 
synergism is dependent upon a distance of 10 base pairs between the binding sites. 
Ten base pairs corresponds to one tum of the double helix. Thus, a stereo-specific 
alignment and a protein-protein interaction between the receptor-ligand complex and 
the other transcription factor is likely. 
In addition to the positive regulation of gene expression outlined above, steroid 
hormone receptors can negatively regulate gene expression. Various mechanisms by 
which intracellular receptors repress gene expression have been described. First, 
binding of a receptor-ligand complex to its HRE can displace a positive regulatory 
factor (Akerbloom et al., 1988; Guertin et al., 1988; Sakai et al., 1988; Beato, 1989; 
Drouin et al., 1989). For example, the occupied glucocorticoid receptor represses 
expression of the human glycoprotein a-subunit gene because the glucocorticoid 
response element overlaps a functional cAMP response element (Akerbloom et al., 
1988). Thus, binding of the glucocorticoid receptor to its HRE sterically hinders the 
binding of the positive transcription factor to the cAMP response element. 
Altered cellular function 
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Figure 6. Pathway of signal transduction of intracellular steroid receptors. The 
steroid (S) diffuses through the cell membrane where it binds to the receptor (R) 
which is complexed to heat shock proteins (hsp). The hsp molecules dissociate, and 
the steroid-receptor complex binds DNA as a homodimer. Binding of the receptor-
ligand complex can lead to transcription of mRNA's, translation of proteins, and 
ultimately an alteration of cellular function. 
A second mechanism by which steroid receptors negatively regulate gene 
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expression involves the regulation of AP-1 mediated induction of gene expression (see 
Figure 7). AP-1 is a transcriptional activator composed of protein dimers of jun and 
fos gene family products. Both Jun-Fos heterodimers and Jun-Jun and Fos-Fos 
homodimers are capable of binding the AP-1 site and inducing gene expression 
(Diamond et al., 1990). However, the Jun-Fos heterodimer binds with higher 
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Figure 7. A model of glucocorticoid regulation of AP- I-mediated transcription of the 
proliferin gene. In each panel the solid line represents the DNA surrounding the 
promoter. The different sized arrows depict relative levels of transcriptional activity. 
In the absence of AP-1 activity the glucocorticoid-receptor complex (GR) does not 
influence transcription (A,B). The Jun homodimer activates transcription (C). The 
GR enhances Jun homodimer-induced transcription (D). The Jun-Fos heterodimer 
strongly activates transcription (E). However, the GR reduces heterodimer-induced 
transcription (F); (adapted from Diamond et al., 1990). 
affinity and more strongly activates gene expression compared to the homodimers. 
Glucocorticoids can both positively and negatively regulate the AP-1 mediated 
induction of the proliferin gene (Diamond et al., 1990). The positive and negative 
regulation of gene expression by glucocorticoids depends upon the intracellular ratio 
of Jun and Fos. The synthetic glucocorticoid, dexamethasone, enhances the 
expression of proliferin activated by Jun homodimers. However, dexamethasone 
reduces Fos homodimer- and Fos/Jun heterodimer-induced gene expression. Thus, 
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interaction of the glucocorticoid receptor with Jun homodimers results in positive gene 
regulation while interaction of the glucocorticoid receptor with Fos/Jun heterodimers 
results in negative regulation of the gene (Diamond et al., 1990). Recently, it was 
demonstrated that binding of the glucocorticoid receptor to the transcription factor, 
AP-1, results in a repression of AP-1 stimulated expression of the collagenase gene 
(Jonat et al., 1990). This direct interaction of a receptor-ligand complex with a 
transcription factor occurs in the absence of DNA binding. Thus, it appears that an 
AP-11 glucocorticoid receptor complex is formed which is unable to trans-activate. 
The mechanism by which specific hormonal regulation of gene transcription is 
attained in vivo has been a fundamental question in the field of steroid receptor 
biology. This is because in vitro several receptors can bind the same DNA binding 
sites (Cato et al., 1988; Ham et al., 1988). For example, glucocorticoids and 
androgens recognize a common HRE. Recent studies have indicated the presence of a 
complex, 120 base pair enhancer of the mouse sex-limited protein (Slp) gene that is 
activated exclusively by androgens and not by glucocorticoids in transfection (Adler et 
al., 1991; Adler et al., 1992; Adler et al., 1993). Hormonal specificity is enforced 
by non-receptor elements within the enhancer (Adler et al., 1992). Androgen-specific 
activation occurs when ligand-activated androgen receptor binds the consensus HRE 
site and interacts with a specific factor on the enhancer to activate transcription (Adler 
et al., 1992). Glucocorticoid receptor may bind the HRE but is unable to 
transactivate (Adler et al., 1992). Selectivity appears to be dependent upon the amino 
terminus of the receptor (Adler et al., 1992). 
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Bef&Ptor Structure 
Comparisons of sequences and functions of the various members of the steroid 
receptor superfamily demonstrate a common basic structure for steroid receptors (for 
rev. see Evans, 1988; see Figure 8). The trans-activation domain (region A/B) lies 
closest to the amino-terminus of the receptor protein. This domain is highly variable 
among the receptors and is responsible for the trans-activation function outlined 
above. This region is also thought to play a role in gene recognition specificity 
(Evans, 1988; Adler et al., 1992). The DNA-binding domain (region C) is a 66-68 
amino acid region rich in cysteine residues which arrange themselves around zinc ions 
forming the "zinc fingers" involved in binding to DNA (for rev. see Evans and 
Hollenberg, 1988). The hinge region (region D) is involved in protein folding 
following hormone-receptor coupling. The ligand-binding domain (region E) is a 
220-250 amino acid region which forms a hydrophobic pocket for steroid binding. 
This region is also the site of hsp90 binding. Surprisingly, neither the ligand-binding 
domain nor the hormone is necessary for DNA binding. Rather, the ligand-binding 
domain prevents the otherwise constitutive binding of the DNA binding domain to the 
HRE, and ligand-receptor coupling relieves this inhibition (Godowski et al., 1987; 
Hollenberg et al., 1987; Waterman et al., 1988). The region closest to the carboxy.:. 
terminus of the receptor (F) is a highly variable region of unknown function. 
The Androgen Rec<a>tor 
The recent cloning and sequence analysis of androgen receptor (AR) cDNA 
reveals a structure similar to other steroid receptors (Lubahn et al., 1988a; Chang et 
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Figure 8. Structural and functional representation of steroid receptors. Receptors 
are divided into six regions (A-F). The A/B region is located at the amino terminus 
and is responsible for the trans-activation function of the receptor. The C region is a 
highly conserved region responsible for DNA binding. The hinge region (D) is 
involved in protein conformational changes. The E region forms a hydrophobic 
pocket for ligand binding. The carboxy terminus of the protein (region F) is highly 
variable and of unknown function (adapted from Evans, 1988). 
al., 1988; for rev. see Janne et al., 1993). The deduced amino acid sequences of rat 
and human AR reveal 902 and 919 amino acid proteins, respectively {Tan et al., 
1988; Lubahn et al., 1988b). The DNA-binding domain of the human AR shares 
greatest homology with progesterone, mineralocorticoid, and glucocorticoid receptors 
(Lubahn et al., 1988a) The amino terminal end (which is characteristically variable 
among steroid receptors) shows little similarity to other receptor sequences (Lubahn et 
al.,1988b). Furthermore, rat and human AR share complete amino acid sequence 
identity in their DNA- and ligand-binding domains (Lubahn et al., 1988b; Tan et al., 
1988). 
Aromatization of Testosterone 
In the brain, testosterone can influence cellular function differentially 
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depending on its intracellular fate (for rev. see McEwen et al., 1982). There are 
threC alternative intracellular fates for testosterone (see Figure 9). Once testosterone 
haS passed through the neuronal membrane, it can bind directly to AR or it can be 
reduced by the intracellular enzyme, 5a-reductase, to DHT which also binds with 
high affinity to AR. Alternatively, testosterone can be converted to 17/j-estradiol by 
the intracellular aromatase enzyme (Weisz and Gibbs, 1974; Naftolin et al., 1975). 
This 17/j-estradiol can then bind to estrogen receptors (ER) and will thus influence 
cellular function in an alternate manner. Thus, the way in which testosterone will 
affect neuronal function in specific brain regions depends on the presence or absence 
of AR, ER, and the aromatase enzyme. 
A recent study suggests that a large proportion of the aromatase-IR cells in the 
quail brain do not contain immunoreactive ER (Balthazart et al. , 1991). In fact, 
significant amounts of aromatase activity are found in synaptosomes purified by 
differential centrifugation (Steimer, 1988; Schlinger and Callard, 1989). Also, 
aromatase immunoreactivity is observed at the light microscopic level in fibers and 
punctate structures (Balthazart et al., 1990) and at the electron microscopic level in 
synaptic boutons (Naftolin et al., 1990). It has been hypothesized that aromatase 
might produce estrogens which act at the synaptic level as neurohormones or 
neuromodulators (Balthazart and Foidart, 1993). Although this is still quite 
speculative, it is possible that aromatization of testosterone may occur in glia and in 
neurons that do not contain ER. The generated 17/j-estradiol may then transfuse to 
ER containing cells. 
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Figure 9. The intracellular fates of testosterone. After diffusing through the cell 
membrane, testosterone can either (1) bind the androgen receptor or (2) be reduced to 
dihydrotestosterone and bind the androgen receptor. Alternatively, testosterone can 
(3) be aromatized to 17/j-estradiol and bind the estrogen receptor. 
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Distribution of Androgen and Estrogen Receptors 
Steroid autoradiographic studies using 3H-DHT (Sar and Stumpf, 1977; 
Sheridan 1978; Doherty and Sheridan, 1981; Wood et al., 1992) revealed androgen 
target cells in the preoptic area, PVN, periventricular, ventromedial, and arcuate 
nuclei of the hypothalamus in rat, mouse, and hamster. High DHT uptake was also 
noted in the amygdala, lateral septum, BNST, and hippocampus. More recently, 
immunohistochemistry and ISHH have revealed similar distributions of AR 
immunoreactivity (Wood and Newman, 1993) and AR mRNA (Simerly et al., 1990). 
It has been reported that the distribution of AR mRNA and CRH in the PVN do not 
overlap (Simerly et al., 1990). However, this is contradicted by observations of AR 
mRNA within this region (Handa, unpublished data). 
The distributions of estrogen-concentrating cells, ER-IR cells, and ER mRNA-
expressing cells have also been described previously (Pfaff and Keiner 1973; Loy et 
al., 1988; Rhodes et al., 1982; Rhodes et al., 1981; Cintra et al., 1986; Don Carlos 
et al., 1991; Pelletier et al., 1988; Simerley et al., 1990). The distribution of these 
estrogen sensitive neurons significantly overlaps the distribution of AR containing 
cells (Sar and Stumpf 1977; Sheridan, 1978; Doherty and Sheridan, 1981; Wood et 
al., 1992; Wood and Newman 1993; Simerly et al., 1990). However, important 
differences exist between the distribution of AR and ER. For example, ER 
immunoreactivity and ER mRNA are abundant within the dorsal zone of the medial 
parvocellular PVN where CRH neurons are localized (Don Carlos et al., 1991; 
Simerly et al., 1990). Also, in the ventral zone of the medial parvocellular PVN 
which contains many cells that project to autonomic regions of the brain stem and 
spinal cord, AR mRNA- but not ER mRNA-containing cells have been observed 
(Simerly et al., 1990). However, this contradicts earlier reports of estrogen 
concentrating cells in this region (Rhodes et al., 1981). 
In the rat the aromatase enzyme is concentrated in several brain regions that 
contain ER such as the preoptic area, medial basal hypothalamus, lateral septum, 
BNST, and amygdala (Naftolin et al., 1975; Selmanoff et al., 1977; Lauber et al., 
1993; Jakab et al., 1993). Thus, testosterone could influence cells in these areas 
through it's aromatization to 17/3-estradiol and subsequent binding to ER. 
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Steroid hormones can influence the sensitivity of target cells to further 
hormonal stimulation. A steroid hormone accomplishes this by regulating the 
expression of genes encoding its own receptor, other steroid receptors, or the 
aromatase enzyme. Androgen receptor and estrogen receptor provide examples of 
homologous regulation of receptor expression (Saceda et al., 1988; Tan et al., 1988; 
Ree et al., 1989; Shupnick et al., 1989; Berthois et al., 1990; Don Carlos et al., 
1990; Quarmby et al., 1990; Shan et al., 1990; Sanborn et al., 1991; Takeda et al., 
1991; Lauber et al., 1992; Lisciotto and Morrell 1993). Examples of heterologous 
regulation of receptor expression include the regulation of androgen receptor and 
progestin receptor by estrogen (Handa et al. , 1987; Handa and Rodriguez, 1991; 
Blaustein et al., 1988; Don Carlos and Morrell, 1989). Furthermore, the induction of 
aromatase activity by androgens represents a limiting factor in the activation of male 
copulatory behavior and has been demonstrated in several species (Connolly et al. , 
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1990; Hutchinson et al., 1990: Weaver and Baum, 1991; Harada et al., 1992; Fadem 
et al., 1993; Harada et al., 1993; Resko et al., 1993; Connolly et al., 1994). Thus, 
steroid hormones can influence the sensitivity of target cells by altering the 
concentration of steroid receptors and the aromatase enzyme. 
Implications and Hypothesis 
In mammals, the biological reaction to anxiogenic stimuli involves well-
characterized neuroendocrine, autonomic, and behavioral changes that serve to protect 
the integrity of the organism. The neuroendocrine system responds with increases in 
plasma ACTH, corticosterone, and prolactin. Autonomic outputs elicit very rapid and 
specific changes including increases in blood pressure and heart rate. In the rat, 
changes in behavior include an increase in freezing and a decrease in rearing. 
Previous studies indicate that androgens affect the HPA axis. Gonadectomized 
male rats have increased CORT and ACTH responses to physical or psychological 
stressors as compared to intact animals (Handa et al., 1994). Furthermore, treatment 
of castrates with testosterone or DHT restores the CORT and ACTH responses to 
these stressful stimuli to that of intact rats. It is important to determine whether 
circulating androgens influence other aspects of the stress response. Thus, our 
hypothesis is that in the male rat, circulating androgens modulate the neuronal 
circuitry responsible for mediating neuroendocrine and behavioral responses to 
stressful stimuli. Dysfunction of the stress response is believed to lead to adjustment 
disorders such as depression and panic disorder. These disorders occur much more 
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often in females than in males (Weissman and Klerman, 1977; Katschnig and 
Amering, 1990). Androgens may play a role in protecting a male from disfunction of 
the stress response. Consequently, the following experiments were designed to 
determine whether androgens influence CRH content, CRH-immunoreactivity, and 
CRH mRNA levels in the PVN. It will be determined whether CRH-containing 
neurons of the PVN contain androgen receptor, thus indicating whether androgens can 
act within these cells to alter hypothalamic CRH levels. Finally, the effects of 
androgens on neuroendocrine, autonomic, and behavioral responses to conditioned 
stress will be examined. 
CHAPI'ER ID 
ANDROGENS INFLUENCE HYPOTHALAMIC CORTICOTROPIN-
RELEASING HORMONE (CRH) AND CRH-IMMUNOREACTIVITY 
FOLWWING GONADECTOMY 
Summary 
To characterize the effect of androgens on the hypothalamo-pituitary-adrenal 
(HPA) axis we examined the regulation of corticotropin-releasing hormone (CRH) 
following gonadectomy and hormone replacement. Three month-old, male Fischer 
344 (F344) rats were gonadectomized (GDX) or sham gonadectomized (SHAM). 
Control animals remained intact. Animals were sacrificed 1, 4, 7, 10, or 21 days 
following surgery. GDX rats had significantly elevated (p<0.05) levels of 
hypothalamic CRH 21 days after surgery compared to intact and sham-operated rats. 
In a second study, three month-old male F344 rats were gonadectomized and treated 
with the non-aromatizable androgen, dihydrotestosterone (DHT) using a Silastic 
capsule containing crystalline DHT propionate subcutaneously implanted in each 
animal's back. Control animals were gonadectomized and sham-treated (GDX) or left 
intact (INT). Three weeks following GDX, CRH levels in the hypothalamus of GDX 
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rats showed a significant increase (p<0.05) compared to intact animals. DHT-
treatment at the time of gonadectomy prevented this increase. CRH or arginine 
vasopressin (A VP) immunoreactivity was examined using immunocytochemistry. The 
number of CRH-immunoreactive (IR) cells in the paraventricular nucleus (PVN) of 
gonadectomized, DHT-treated animals was significantly decreased (p<0.05) 
compared to GDX rats. No differences were seen between treatment groups in CRH-
IR cell numbers in the bed nucleus of the stria terminalis or the central amygdaloid 
nucleus or in AVP-IR cell numbers in the PVN. These data demonstrate that long 
term castration increases hypothalamic CRH content and CRH-IR cell numbers in the 
PVN by removal of an androgen-dependent repression. 
Introduction 
The hypothalamo-pituitary-adrenal (HPA) axis is a principle component of an 
animal's adaptive response to environmental perturbations. Neurons located in the 
parvocellular region of the paraventricular nucleus (PVN) of the hypothalamus project 
to the median eminence where they secrete a 41-amino acid peptide, corticotropin-
releasing hormone (CRH), into the portal vasculature. Corticotropin-releasing 
hormone then stimulates corticotrophs of the anterior pituitary to secrete 
adrenocorticotropic hormone (ACTH) which in tum stimulates the secretion of 
corticosterone (CORT) from the adrenal cortex. 
Products of the HP A axis have been shown to inhibit reproductive function by 
suppressing both gonadotropin secretion (Rivier and Vale, 1984; Rivier and Vale, 
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19s5b; Rivier et al., 1986; Kamel and Kubajak, 1987) and reproductive behaviors 
(Plas-Rose and Aron, 1981; Sirinathsinghji et al., 1983; Armstrong, 1986; 
sirinathsinghji et al., 1986). Conversely, gonadal hormones are known to affect HPA 
activity. Previous studies have demonstrated a significant sex difference in circulating 
CORT levels and in the CORT response to stress with females having higher levels 
than males (Kitay, 1961). The greater secretion in females is believed to be the result 
of estrogen acting to enhance HPA activity (Kitay, 1963; Viau and Meaney, 1991a; 
Burgess and Handa, 1992). 
In contrast, in males androgens may inhibit HP A activity (Critchlow et al., 
1963; Gaskin and Kitay, 1971; Handa et al., 1994; Viau and Meaney, 1991b). 
Previous studies have shown that prepuberal gonadectomy of the male rat and hamster 
lead to enhanced levels of CORT which correlate with increases in ACTH bioactivity 
(Critchlow et al., 1963; Gaskin and Kitay, 1971). Consistent with these findings, we 
have shown that, following foot shock stress or exposure to a novel environment, 
plasma CORT and ACTH levels are higher in gonadectomized male rats as compared 
to intact animals. Furthermore, gonadectomized rats receiving replacement 
testosterone or the non-aromatizable androgen, dihydrotestosterone (DHT), have post-
stress plasma CORT and ACTH levels similar to that seen in intact animals (Handa et 
al., 1994). These data support the hypothesis that the sex difference in HPA activity 
arises as a result of the circulating gonadal steroid environment. 
Several possible mechanisms could explain androgen's inhibition of HPA 
activity. Androgens could be inhibiting synthesis and secretion of hypothalamic CRH 
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(or other corticotropin-releasing factors such as arginine vasopressin, AVP), 
enhancing the negative feedback of the HP A axis, or decreasing anterior pituitary 
sensitivity to CRH. The hypothesis that androgens influence the negative feedback 
response is not supported because there are no differences in either concentration or 
affinity of type I or type II CORT receptors in the hippocampus or hypothalamus in 
intact versus castrated rats (Handa et al., 1994). Furthermore, anterior pituitary 
responsiveness to CRH does not appear to be altered following gonadectomy of male 
rats (Handa et al., 1994). The possibility remains that androgens could be 
influencing hypothalamic CRH synthesis and secretion. 
In order to determine whether androgens affect the HP A axis by inhibiting 
hypothalamic CRH levels, we examined the effect of the non-aromatizable androgen, 
DHT, on hypothalamic CRH content and CRH-immunoreactive (IR) cell numbers 
within the PVN. 
Materials and Methods 
Animals 
Three month old, male Fischer 344 rats (F344, Harlan/Sprague Dawley, 
Indianapolis, IN) were maintained on a 12: 12 light: dark schedule with lights on at 
0700h. Animals were housed in temperature controlled rooms. Food and water were 
available ad libitum. For timecourse studies, animals were either bilaterally 
gonadectomized (GDX) or received a sham operation (SHAM) under ether anesthesia. 
Control animals remained intact (INT). Animals were sacrificed 1, 4, 7, 10,. or 21 
54 
days after surgery between 0900 and llOOh. Animals were sacrificed by decapitation 
immediately following removal from their home cage. Hypothalami were dissected 
for evaluation of CRH content. To study the effects of androgen-replacement in 
castrates, 3 month-old male F344 rats were bilaterally gonadectomized under ether 
anesthesia. Gonadectomized animals received either hormone replacement using a 2.5 
cm Silastic capsule (0.07" I.D., 0.125" 0.D.; Dow Coming, Midland, Ml) 
containing crystalline dihydrotestosterone propionate (DHT) subcutaneously implanted 
in each animal's back (GDX+DHT) or a sham incision (GDX). Control animals 
were left intact (INT). Animals were sacrificed 21 days after surgery between 0900 
and 1100 h. For measurement of hypothalamic CRH content, animals were sacrificed 
by decapitation immediately following removal from their home cage. Trunk blood 
was collected into tubes containing 300 µl 0.3 M ethylenediaminetetraacetic acid 
(EDTA). Plasma was frozen (-80°C) until assayed for testosterone and DHT. For 
immunocytochemical studies, animals were anesthetized with a lethal dose (0.13 
mg/kg) of sodium pentabarbital and perfused through the ascending aorta with 4 % 
buffered paraformaldehyde. Blood was taken by cardiac puncture just prior to 
perfusion and added to tubes containing 300 µl 0.3 M EDTA. Animals were NOT 
treated with colchicine prior to sacrifice because the resulting accumulation of CRH 
could mask treatment effects. 
CRH Radioimmunoassay (RIA) 
Hypothalami were dissected according to the following landmarks: the .optic 
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cbiaSm rostrally, the mammillary bodies caudally, the roof of the third ventricle 
dorsally, the infundibulum ventrally, and the hypothalamic sulci laterally. Tissue was 
homogenized in 1 ml 0.1 N HC1:2 N acetic acid (1: 1), boiled for 3 minutes, and 
centrifuged at 2000 x g for 20 minutes. The supernatant was dessicated in a 
Centrivap concentrator (Labconco, Kansas City, MO) and stored at -800 C until 
assayed. CRH content was measured by RIA using anti-CRH serum (Peninsula 
Laboratories, Belmont, CA) raised against synthetic CRH (human, rat). 125!-CRH 
(NEN, Boston, MA) was used as the tracer. Protein concentration in the pellets 
recovered following the 2000 x g centrifugation was determined by the method of 
Lowry, et al. (1951). The ED50 was 30.65 pg/tube. The assay limit of detectability 
was 11.8 pg/tube. The intra- and inter-assay coefficients of variance were 3.6% and 
10.2%, respectively. 
Immunocytochemistry 
Brains were post-fixed overnight in 4% paraformaldehyde in borate buffer, and 
20 µm-thick coronal sections were cut through the forebrain with a vibratome 
(Technical Products Intl., St. Louis, MO). Every fourth section was used for 
evaluation of CRH immunoreactivity. Adjacent sections were used for evaluation of 
arginine vasopressin (A VP) immunoreactivity. The following primary antisera were 
used in this study: anti-corticotropin-releasing hormone (lot #465) provided by the 
late Dr. T.L. O'Donohue, and anti-arginine vasopressin (48 bleed 10) provided by 
Dr. S.J. Watson (Univ. of Michigan, Ann Arbor). Free floating sections were 
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incubated with antiserum diluted at either 1:2000 (CRH) or 1:10,000 (AVP) in 0.1 M 
phosphate buffered saline with 0.25% Triton X-100 (Malinkrodt, Inc., Paris, KY) and 
2% normal donkey serum for 18-24 hours at 4°C. Immunoreactivity was visualized 
using a biotinylated secondary antibody, streptavidin-horseradish peroxidase, and 
diaminobenzidine. Sections were mounted on gel-coated slides, and CRH-IR cells in 
the PVN, bed nucleus of the stria terminalis (BNST), and central amygdaloid nucleus 
(CeA), and A VP-IR cells in the PVN were counted without knowledge of treatment 
group. Labelled cells were distinguished based on the discretion of the examiner. 
The number of counted cells were multiplied by 4 (every fourth section was used) and 
corrected for double-counting errors according to Abercrombie (1946). 
As a control for antisera specificity, 1 ml of each diluted antiserum was 
preincubated with 50 µg of its respective synthetic neuropeptide, and the sections 
were processed as usual to determine whether any residual staining remained. 
Although immunohistochemical staining was eliminated in these controls, it is possible 
that these antisera may recognize unidentified neuropeptides containing similar amino 
acid sequences. Thus, the neuropeptide immunoreactivity detected in this study is 
more accurately described as neuropeptide-like immunoreactivity. 
Steroid Radioimmunoassays 
Plasma testosterone and DHT levels were evaluated by RIA using a mI-
testosterone kit (ICN Biomedicals, Inc., Casa Mesa, CA). The standard curve ranged 
from 5 to 500 pg/tube. Bound and free steroid were separated using a goat anti-rabbit 
gamma-globulin. The RIA sensitivity limit was 1.98 pg/tube. The intra-assay 
coefficient of variance was 9.5%. All values were analyzed in one assay to avoid 
inter-assay variation. 
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For plasma DHT determination, steroids were extracted from samples using 
hexane:ethyl acetate (3:2) and separated on microcelite columns (ICN Biomedicals, 
Inc.) using an isooctane-ethyl acetate system. DHT was eluted from the column with 
5% ethyl acetate in isooctane. Recovery of DHT was 80%. Plasma DHT was 
determined by RIA using a 3H-dihydrotestosterone RIA kit (ICN Biomedicals, Inc.). 
The standard curve ranged from 10 to 500 pg/tube. Bound and free steroid were 
separated using dextran-coated charcoal. The RIA sensitivity limit was 30.3 pg/tube. 
The intra-assay coefficient of variance was 10.9%. All values were analyzed in one 
assay to avoid inter-assay variation. 
Statistics 
Time course data were analyzed by two-way analysis of variance across 
treatment and time (Winer, 1977). Data from DHT-replacement studies were 
analyzed by one-way analysis of variance (Winer, 1977). Plasma DHT levels were 
analyzed by a two-tailed t-test (Winer, 1977). A p value of < 0.05 was considered 
significant. Newman-Keuls' test was used for post hoc analysis. 
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Results 
l1JrP91halamic CRH Levels 
Radioimmunoassayable CRH content in the hypothalamus was significantly 
increased (p<0.05) in GDX rats as compared to intact animals 21 days after surgery 
(Figure 10). Sham gonadectomy had no effect on hypothalamic CRH content across 
any time point examined. Hypothalmic CRH content in intact male F344 rats 
averaged 1.6 + 0.1 ng/hypothalamus. DHT administered continuously from the time 
of gonadectomy prevented the effect of GDX 21 days after surgery (Figure 11). 
Plasma testosterone and DHT levels are shown in Table 3. Gonadectomy reduced 
circulating androgens, and hormone treatment increased DHT titers. 
Immunocytochemistry 
Corticotropin-releasing hormone-IR cell numbers were significantly greater 
(p<0.05) in the PVN of GDX male rats as compared to GDX animals receiving 
replacement DHT titers (Figure 12). When CRH-IR cell numbers in the PVN of 
GDX and GDX + DHT rats were expressed as a percent of the intact cell count for 
each immunocytochemical reaction, GDX rats had 198.1 + 47.3% and rats in the 
GDX + DHT group had 63.2 + 12.0% of the CRH-IR cell numbers seen in intact 
animals. No significant differences were seen in CRH-IR cell numbers in the BNST 
or CeA between the treatment groups. Furthermore, no significant differences were 
seen between treatment groups in A VP-IR cell numbers in the PVN. Representative 
coronal sections demonstrating CRH-IR cells and A VP-IR cells in the PVN of intact, 
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Figure 10. Hypothalamic CRH content in gonadectomized (GDX) and sham 
gonadectomized (SHAM) male F344 rats 1, 4, 7, 10, or 21 days following surgery. 
Values were determined by radioimmunoassay and expressed as a percent of the mean 
hypothalamic CRH content of intact male rats (INT) run with each assay. 
Hypothalamic CRH content of intact rats averaged 1.6 + 0.1 ng/hypothalamus. 
*significant difference (p< .05) from intacts. #significant difference (p< .01) from 
21-day shams. n=5-12/group. Each point represents the mean + the standard error 
of the mean of values obtained from individual rats within each treatment group. 
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Figure 11. Hypothalamic CRH content in intact (INT), gonadectomized (GDX), and 
gonadectomized, dihydrotestosterone-treated (GDX + DHT) male F344 rats 
determined by radioimmunoassay and expressed as pg CRH/mg protein. Animals 
were gonadectomized 3 weeks prior to sacrifice. DHT was administered at the time 
of gonadectomy using a 2.5 cm Silastic capsule containing crystalline DHT propionate 
implanted under the skin of each animal's back. *designates groups which are 
significantly different (p<0.05) from intact animals. #designates groups which are 
significantly different (p<0.05) from DHT-treated animals. n=5-6/group. Each bar 
represents the mean + standard error of the mean of values obtained from individual 
rats within each treatment group. 
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Figure 12. CRH-IR and AVP-IR cell numbers in the paraventricular nucleus (PVN), 
bed nucleus of the stria terminalis (BNST) and central nucleus of the amygdala (CeA) 
of male F344 rats. Animals were either intact (INT) or bilaterally gonadectomized 
under ether anesthesia. Half of the gonadectomized animals received either 
dihydrotestosterone (GDX + DHT) or a sham operation (GDX). DHT was 
administered continuously for the duration of gonadectomy using a 2.5 cm Silastic 
capsule containing crystalline DHT propionate subcutaneously implanted in each 
animal's back. * GDX and GDX + DHT groups are significantly different at 
p<0.05. n=5-8/group. Each bar represents the mean + standard error of the mean 
of values obtained from individual rats within each treatment group. 
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Figure 13. Bright-field photomicrographs showing CRH-immunoreactive cells 
(A,B,C) and AVP-immunoreactive cells (D) within the paraventricular nucleus of 
intact (A), gonadectomized (B,D), and gonadectomized, dihydrotestosterone- (DHT) 
treated (C) male F344 rats. Animals were gonadectomized 3 weeks prior to sacrifice. 
DHT was administered continuously from the time of gonadectomy using a 2.5 cm 
Silastic capsule containing crystalline DHT propionate subcutaneously implanted in 
each animal's nape. The third ventricle is on the right. Bar = 100 µm. 
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TABLE 3. Plasma testosterone and dihydrotestosterone (DHT) levels in intact, 
gonadectomized, and gonadectomized, DHT-treated male F344 rats determined by 
radioimmunoassay. a,b 
Ireatment" 
INT 
GDX 
GDX + DHT 
Testosterone (n)d,e 
1.267 + .167 (10) 
ND (9) 
ND (9) 
DHT (n)d,e 
.255 + .065 (7) 
ND (5) 
1.538 + .123 (6)* 
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8Animals were gonadectomized 3 weeks prior to sacrifice. DHT was administered at 
the time of gonadectomy using a 2.5 cm Silastic capsule containing crystalline DHT 
propionate implanted under the skin of each animal's back. 
bPlasma hormone levels were determined in animals used for both CRH 
radioimmunoassay and immunocytochemistry. 
cINT, intact; GDX, gonadectomized; GDX + DHT, gonadectomized, DHT-treated 
dvalues expressed in ng/ml 
en, number of animals per group 
ND designates values too low to detect. The limits of detectability were 0.040 ng/ml 
for testosterone and 0.145 ng/ml for DHT. 
* Plasma DHT levels of GDX + DHT animals were significantly (p < .01) higher 
than in intact animals. 
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GDX, and GDX + DHT rats are shown in Figure 13. 
Discussion 
These data demonstrate that long term castration increases hypothalamic CRH 
concentration. This increase in CRH in the gonadectomized male rat correlates with 
the increased CORT and ACTH responses to physical and psychological stressors 
previously observed in the gonadectomized male rat (Handa et al., 1994; Viau and 
Meaney, 199lb) and suggests that this pool of CRH is readily releasable. Although a 
previous study suggested that prepuberal gonadectomy of male rats did not affect 
hypothalamic content of corticotropin-releasing bioactivity (Coyne and Kitay, 1971), 
our data are consistent with a more recent study showing increases in hypothalamic 
CRH peptide levels following long term castration (Almeida et al., 1992). Also 
consistent with this study, we report here that greater than ten days is necessary to see 
an effect of castration on hypothalamic CRH content. This effect is most probably 
due to a release of inhibition by androgens since we have demonstrated that androgen 
replacement restores hypothalamic CRH concentration to that of the intact animal. 
This inhibition appears to be an androgen receptor-mediated event as the non-
aromatizable androgen, DHT, was effective in suppressing castration-induced 
increases in hypothalamic CRH concentration. Although it may appear that the levels 
of plasma DHT in the DHT-treated castrates were supra-physiologic, it was our 
intention to replace the total androgen (testosterone and DHT) lost due to the 
gonadectomy. It should also be noted that our values for hypothalamic CRH .content 
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are in the range of those previously reported (Almeida et al., 1992). 
We have demonstrated that CRH-IR cell numbers in the PVN of 
gonadectomized male rats are greater than in gonadectomized rats receiving 
replacement DHT titers. This suggests that in the absence of androgens CRH 
synthesis or storage may be increased such that more cells can be detected 
immunocytochemically. Alternatively, a subpopulation of cells within the PVN may 
begin to synthesize CRH. It should be noted that the effect of androgens on CRH-IR 
cell numbers in the PVN reported here was observed in animals that were not pre-
treated with colchicine. The accumulation of CRH that results from treatment with 
colchicine could mask the effect of gonadal steroids on CRH immunoreactivity. 
Whether androgen-induced changes in CRH-IR cell numbers and hypothalamic 
CRH concentration occur as a result of changes in synthesis or degradation of CRH is 
unknown. However, recent studies showing that CRH mRNA levels in the PVN are 
not altered by short- or long-term castration (Almeida et al., 1992) suggest that CRH 
synthesis may not be responsible for the increases in CRH content and CRH-IR cell 
numbers observed in the present study. 
In the brain, testosterone can act as either an androgen or an estrogen 
depending upon its intracellular fate (for rev. see McEwen and Parsons, 1982). After 
testosterone has passed through the neuronal membrane, it can bind directly to 
androgen receptor or it can be reduced by the intracellular enzyme, 5a-reductase, to 
DHT which also binds with high affinity to androgen receptor. Alternatively, if the 
aromatase enzyme is present within the cell, testosterone can be converted to 17{3-
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estradiol (Weisz and Gibbs, 1974; Naftolin et al., 1975). This 17/j-estradiol can then 
bind to estrogen receptors and will thus influence cellular function in an alternate 
manner. The effect of androgens on hypothalamic CRH concentration and CRH-IR 
cell numbers in the PVN appears to be an androgen receptor-mediated phenomenon as 
the non-aromatizable androgen, DHT, was effective in reversing the effects of 
castration. It is uncertain, however, whether androgens are acting directly on CRH 
containing neurons in the PVN. Although both [3H]-DHT uptake (Sar and Stumpf, 
1977) and androgen receptor mRNA (Simerly et al., 1990) have been detected in the 
PVN, androgen receptor mRNA may not be localized in the parvocellular region of 
the PVN where CRH containing neurons are found (Simerly et al., 1990). 
Consequently, androgens may exert an effect on the PVN transsynaptically as 
androgen receptor (Sar and Stumpf, 1977; Sheridan, 1979; Randa et al., 1987) and 
androgen receptor mRNA (Simerly et al., 1990) are found within brain regions which 
project (directly or indirectly) to the PVN such as the BNST (Swanson and Cowan, 
1979; Silverman et al., 1981) and hippocampus (for rev. see Jacobson and Sapolsky, 
1991). Furthermore, the effect of androgens on CRH-IR cell numbers appears to be 
region-specific as no differences were seen among the treatment groups in either the 
BNST or the CeA. This region-specificity of androgen action might better be 
explained by a transsynaptic mechanism such as that hypothesized for steroidal 
regulation of gonadotropin-releasing hormone (Petraglia et al., 1984; Bhanot and 
Wilkinson, 1985; Gabriel et al., 1986; Wehrenberg et al., 1989; Kalra et al., 1990; 
Sahu et al., 1990; Huang and Harlan, 1993). 
Arginine vasopressin (A VP) is present in both intra- and extrahypothalamic 
siteS (Buijs, 1978). AVP has been colocalized with CRH in hypothalamic neurons 
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and potentiates the effect of CRH on ACTH secretion (Gillies et al., 1982; Antoni et 
al., 1983; Rivier et al., 1984b; Sawchenko et al., 1984; Roth et al., 1982). The 
density of AVP fibers originating in the BNST (DeVries and Buijs, 1983) and 
innervating the lateral septum and lateral habenular nucleus is higher in males than in 
females (DeVries et al., 1981). Furthermore, this sex difference is dependent on the 
neonatal presence of testosterone (De Vries et al., 1983). In the adult animal, 
androgens appear to maintain this sex difference since gonadectomy of male rats leads 
to a disappearance of A VP-IR cell bodies in the BNST (De Vries et al., 1985; Miller 
et al., 1992) and medial amygdala without affecting A VP-IR cell bodies in the PVN 
(De Vries et al., 1985). Our studies also demonstrate that A VP-IR cell numbers in the 
PVN were not influenced by the androgen status of the animal. While it is clear that 
androgens can regulate A VP expression in some brain regions, changes in the A VP 
system would not explain changes noted in the CORT and ACTH response to stress 
noted in the castrated male rat (Handa et al., 1994; Viau and Meaney, 1991b). 
In summary, the results of the present study demonstrate that castration 
increases and androgens decrease hypothalamic CRH content and CRH-IR cell 
numbers in the PVN. These parameters can be influenced by synthesis in the soma, 
secretion from the terminals, and degradation of the neuropeptide. It is unknown at 
this point which of these factors is altered by androgens. Additionally, while our data 
indicate that androgen's influence on the HPA axis occurs, at least in part, at the level 
69 
of the hypothalamus, it should not be inferred that androgens act directly on the 
hypothalamus. The PVN is a highly integrated and regulated cell group (for rev. see 
Swanson and Sawchenko, 1983), and many possible target sites exist at which gonadal 
steroids could act to ultimately regulate CRH cells within the PVN. There may exist 
a complex pathway by which the circulating gonadal hormone milieu influences 
adaptive physiological responses to environmental perturbations. It is clear that an 
extensive interrelationship exists between the HPA and the hypothalamo-pituitary-
gonadal axes. 
CHAYfER IV 
CIRCULATING ANDROGENS DO NOT ALTER 
CORTICOTROPIN-RELEASING HORMONE mRNA LEVELS IN THE 
PARA VENTRICULAR NUCLEUS OF THE HYPOTHALAMUS 
Summary 
Previous studies demonstrate that long term castration increases hypothalamic 
corticotropin-releasing hormone (CRH) content and CRH immunoreactivity in the 
paraventricular nucleus of the hypothalamus (PVN) of male rats by removal of an 
androgen-dependent repression. To characterize the effect of androgens on 
hypothalamic CRH, we examined the effect of gonadectomy and androgen treatment 
on CRH mRNA levels in the PVN of male rats. Three month-old, male Fischer 344 
(F344) rats were bilaterally gonadectomized under ether anesthesia. Gonadectomized 
animals received either the non-aromatizable androgen, dihydrotestosterone (DHT), 
using a Silastic capsule containing crystalline DHT propionate subcutaneously 
implanted in each animal's back (GDX+DHT) or a sham incision (GDX). Control 
animals remained intact. For positive controls, male rats were adrenalectomized 
(ADX) and sacrificed seven days after surgery. Corticotropin-releasing hormone 
mRNA was examined by in situ hybridization histochemistry using a 35S-labelled 
oligonucleotide probe complementary to nucleotides 496-543 of rat CRH mRNA. 
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.Arginine vasopressin (AVP) mRNA was similarly evaluated using a 35S-labelled 
oligonucleotide probe complementary to nucleotides 286-315 of prepro-AVP mRNA. 
image analysis of hybridization density in the PVN showed no significant differences 
in CRH mRNA or A VP mRNA between intact, GDX, and GDX + DHT animals 
sacrificed 3 weeks after surgery. Similarly, the numbers of CRH mRNA-labelled 
cells in the dorsal medial parvocellular, dorsal parvocellular, and ventral medial 
parvocellular subdivisions of the PVN and the numbers of A VP mRNA-labelled cells 
in magnocellular and parvocellular subdivisions of the PVN were not altered 3 weeks 
after gonadectomy. In addition, there were no significant differences in CRH mRNA 
hybridization in the PVN or in the numbers of CRH mRNA-labelled parvocellular 
neurons among intact, GDX, and GDX, DHT-treated rats sacrificed 10 days after 
surgery. These data suggest that changes in hypothalamic CRH content and CRH 
immunoreactivity in the PVN after gonadectomy cannot be explained by changes in 
CRH gene expression. 
Introduction 
Activation of the hypothalamo-pituitary adrenal (HPA) axis is a major 
component of an organism's adaptive biological reaction to stressful stimuli. In 
response to stress, neurosecretory cells in the parvocellular portion of the 
paraventricular nucleus of the hypothalamus (PVN) synthesize and secrete 
corticotropin-releasing hormone (CRH) into the hypohysial portal vasculature. CRH 
serves as the major physiological stimulus promoting the secretion of 
adfenoeorticotropic hormone (ACTH) from the anterior pituitary. ACTH 
subsequently causes the adrenal cortex to secrete corticosterone (CORT) into the 
peripheral circulation. During stress, corticosterone influences several physiological 
parameters including glucose mobilization, inflammation, and water resorption. 
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The interactions that take place between the HP A axis and the hypothalamo-
pituitary-gonadal axis have been widely studied. Hypothalamo-pituitary-adrenal axis 
hormones inhibit gonadotropin secretion and reproductive behavior (Rivier and Vale, 
1984; Rivier and Vale, 1985b; Rivier et al., 1986; Kamel and Kubajak, 1987; Plas-
Rose and Aron, 1981; Sirinathsinghji et al., 1983; Armstrong, 1986; Sirinathsinghji 
et al., 1986). Conversely, gonadal hormones affect HPA activity. In rats, females 
have higher circulating CORT levels and higher CORT responses to stress than males 
(Kitay, 1961). Estrogen contributes to this sex difference by increasing HPA activity 
(Kitay, 1963; Viau and Meaney, 1991a; Burgess and Handa, 1992). In contrast, 
circulating androgens may inhibit HPA activity (Critchlow et al., 1963; Gaskin and 
Kitay, 1971; Handa et al., 1994). 
Circulating androgens appear to regulate the HP A axis, at least in part, at the 
level of the hypothalamus. Previous studies have demonstrated that hypothalamic 
CRH content is increased following gonadectomy of male rats (Bingaman et al. , 
1994). In addition, treatment of gonadectomized rats with dihydrotestosterone (DHT) 
normalizes hypothalamic CRH content to that of intact animals. This is consistent 
with studies which indicate that the ACTH and corticosterone responses to a physical 
or psychological stressor are increased in gonadectomized male rats (Handa et al. , 
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1994; Viau and Meaney, 1991b). 
Several mechanisms could explain the regulation of hypothalamic CRH by 
androgens. Possibilities include an increased synthesis or half-life of CRH or a 
decrease in axoplasmic transport and/or secretion following gonadectomy. This 
experiment was performed to determine whether the influence of androgens on CRH 
content and CRH immunoreactivity in the hypothalamus is a consequence of changes 
in CRH gene expression. Corticotropin-releasing hormone mRNA levels in the PVN 
of intact, gonadectomized, and gonadectomized, DHT-treated male rats were 
evaluated using in situ hybridization histochemistry (ISHH). Arginine vasopressin 
(A VP) mRNA levels in the PVN of these animals were similarly evaluated due to 
AVP's role as a corticotropin-releasing factor. 
Changes in CRH content may reflect concurrent changes in CRH mRNA. 
Alternatively, in the castrate CRH synthesis may increase briefly and then return to 
steady state once the larger CRH pool is established. If the latter case is true, the 
transient increase in mRNA levels would be expected to precede changes in protein 
content. Since hypothalamic CRH content begins to increase 10 days after 
gonadectomy (Bingaman et al., 1994) with a significant increase by 21 days after 
castration CRH mRNA levels were evaluated at 10 or 21 days following surgery. 
Materials and Methods 
Animals and Surgezy 
Three month-old, male Fischer 344 rats (F344, Harlan/Sprague Dawley, 
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Indianapolis, IN) were maintained on a 12: 12 light:dark schedule with lights on at 
07()()h. Animals were housed in temperature controlled rooms. Food and water were 
available ad libitum. Rats were bilaterally gonaclectomized under ether anesthesia. 
Gonadectomized animals received either hormone replacement using a 2.5 cm Silastic 
capsule (0.07" I.D., 0.125" O.D.; Dow Coming, Midland, MI) containing crystalline 
DHT propionate subcutaneously implanted in each animal's back (GDX+DHT) or a 
sham incision (GDX). Control animals were left intact (INT). Animals were 
sacrificed either 10 or 21 days after surgery between 0900 and 1100 h. For positive 
controls, three month-old male F344 rats were adrenalectomized under ether 
anesthesia (ADX) and sacrificed seven days after surgery. All animals were 
sacrificed by decapitation immediately following removal from their home cage. 
Trunk blood was collected into tubes containing 300 µl 0.3 M 
ethylenediaminetetraacetic acid (EDTA). Plasma was frozen (-80°C) until assayed for 
testosterone and DHT. 
Tissue Pre.paration 
Brains were immediately removed, blocked, and frozen in isopentane (-20°C) 
for 30 seconds and then placed on dry ice. Brains were stored at -800C until 18 µm-
thick frontal sections were cut on a cryostat. Sections were cut to include the PVN. 
Sections were stored dessicated and frozen (-80°C) until use. 
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~on of Labelled Probes 
Oligonucleotide probes complementary to nucleotides 496-543 of rat CRH 
mRNA and nucleotides 286-315 of prepro-AVP mRNA were radiolabelled by poly-A 
tailing in the presence of 35S-ATP (NEN; Boston, MA) using terminal 
deoxynucleotidyl transferase (Boehringer Mannheim; Indianapolis, IN). The specific 
activity of the CRH oligonucleotide probe was approximately 3.20x1018 dpm/mol. 
The specific activity of the AVP oligonucleotide probe was approximately 3.43xl018 
dpm/mol. 
In Situ Hybridization 
Every fourth section was used for evaluation of CRH mRNA levels. Sections 
were processed for ISHH using the 35S-labelled oligonucleotide probe complementary 
to nucleotides 496-543 of rat CRH mRNA. Adjacent sections from rats treated for 21 
days were analyzed using the 35S-labelled oligonucleotide probe complementary to 
nucleotides 286-315 of prepro-AVP mRNA. Sections were warmed to room 
temperature, fixed in 4% formaldehyde, acetylated with 0.25% acetic anhydride in 
O. lM triethanolamine/0.9% NaCl before dehydrating and delipidating in ethanols and 
chloroform, respectively, and subsequent air drying. Radiolabelled probe was added 
at a concentration of approximately 1.5 x 106 cpm/slide in 100 µl of hybridization 
buffer (600mM NaCl, lOmM Tris-HCl, 0.02 % Denhart's, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 0.1 mg/ml denatured Herring testis DNA, 
0.5 mg/ml total yeast RNA, 0.05 mg/ml yeast tRNA, 10% dextran sulfate, 0.05% 
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sadium thiosulfate, 50 mM DTI, 0.05% sodium dodecylsulfate (SDS), 50% 
tormamide). Hybridization was performed overnight (16-20 hours) at 37°C. 
Nonspecific binding was removed by washing in 2xSSC at room temperature (lxSSC 
== o.15 M NaCl, 0.015 M sodium citrate, pH 8.0), 2xSSC/50% formamide at 40°C, 
and lx SSC at room temperature. Following dehydration in ethanols and drying 
slides were apposed to Hyperfilm (3-max (Amersham; Arlington Heights, IL). 
Autoradiograms were analyzed by image analysis of hybridization density. 
Hybridized regions of the PVN were outlined using NIH Image software. The 
density within was measured by comparison to a standard curve created by a slide of 
14c standards (Amersham, Arlington Heights, IL) which were converted to their 35S 
equivalents expressed as dpm/mg protein. (14C standards are used rather than 35S due 
to the long half-life of 14C.) Next, sections were dipped in Kodak NTB-3 nuclear 
emulsion and exposed in a light-tight box for 3 112 weeks (CRH) or 3 days (AVP). 
Sections were then stained with cresyl violet and labelled cells were counted under 
darkfield microscopy. A cresyl violet-stained nucleus surrounded by exposed silver 
grains was considered to be a radiolabelled cell. CRH mRNA expressing cells were 
counted in three separate areas of the PVN (dorsal medial parvocellular, ventral 
medial parvocellular, and dorsal parvocellular) as described by Swanson and Simmons 
(1989). These areas are those in which CRH neurons are concentrated and were 
quantified separately so that changes in any one functional division would not be 
masked by lack of changes in other regions. Similarly, cells radiolabelled with the 
A VP mRNA probe were counted separating cells observed in the magnocellular and 
parvocellular subdivisions. Cell counts were corrected for double-counting errors 
(Abercrombie, 1946) . 
.steroid Radioimmunoassays 
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Plasma testosterone levels were evaluated by radioimmunoassay (RIA) using a 
1251-testosterone kit (ICN Biomedicals, Inc., Casa Mesa, CA). The standard curve 
ranged from 5 to 500 pg/tube. Bound and free steroid were separated using a goat 
anti-rabbit gamma-globulin. The RIA sensitivity limit was 1.98 pg/tube. The intra-
assay coefficient of variance was 9.5%. All values were analyzed in one assay to 
avoid inter-assay variation. 
For plasma DHT determination, steroids were extracted from samples using 
hexane:ethyl acetate (3:2) and separated on microcelite columns (ICN Biomedicals, 
Inc.) using an isooctane-ethyl acetate system. Dihydrotestosterone was eluted from 
the column with 5 % ethyl acetate in isooctane. Recovery of DHT was evaluated by 
adding a known amount of 3H-DHT to the plasma sample prior to placement on the 
column. Recovery of DHT was 80 % . Plasma DHT was determined by RIA using a 
3H-dihydrotestosterone RIA kit (ICN Biomedicals, Inc.). The standard curve ranged 
from 10 to 500 pg/tube. Bound and free steroid were separated using dextran-coated 
charcoal. The RIA sensitivity limit was 30.3 pg/tube. The intra-assay coefficient of 
variance was 10.9%. All values were analyzed in one assay to avoid inter-assay 
variation. 
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SlatistlCS 
The data are represented as the group means and the standard errors of the 
mean (S.E.M.). In situ hybridization histochemistry data were analyzed by one-way 
analysis of variance, and Newman-Keuls' test was used for post hoc analysis (Winer, 
1977). Plasma DHT levels were analyzed by a two-tailed t-test (Winer, 1977). A p 
value of < 0. 05 was considered significant. 
Results 
Plasma testosterone and DHT concentrations are shown in Table 4. 
Gonadectomy reduced circulating androgens, and hormone treatment increased DHT 
titers. It may appear as though the levels of plasma DHT in the DHT-treated 
castrates were supra-physiologic. However, it was our intention to replace the total 
androgen (testosterone and DHT) lost due to gonadectomy. 
Figure 14 shows the hybridization density of a 35S-labelled oligonucleotide 
probe for CRH mRNA in the PVN of INT, GDX, GDX + DHT, and ADX animals. 
Hybridization of the 35S-labelled probe to CRH mRNA was significantly increased 
(p < . 05) in the PVN of adrenalectomized animals compared to INT animals. 
However, there were no significant differences in hybridization density in the PVN 
between INT, GDX, and GDX+DHT animals 21 days after surgery. Figure 15 
Table 4. Plasma testosterone and dihydrotestosterone (DHT} levels in intact, 
gonadectomized, and gonadectomized, DHT-treated male F344 rats determined by 
radioimmunoassay. a 
INT 
GDX 
GDX + DHT 
Testosterone (n)C·d 
0.65 + 0.14 (11) 
ND (11) 
ND (9) 
DHT (n)C·d 
0.24 + 0.05 (7) 
ND (9) 
1.50 + 0.16 (6)* 
aAnimals were gonadectomized 10 days or 3 weeks prior to sacrifice. DHT was 
administered at the time of gonadectomy using a 2.5 cm Silastic capsule containing 
crystalline DHT propionate implanted under the skin of each animal's back. 
bINT, intact; GDX, gonadectomized; GDX + DHT, gonadectomized, DHT-treated 
'Values expressed in ng/ml 
dn, number of animals per group 
ND designates values too low to detect. The limits of detectability were .040 ng/ml 
for testosterone and 0.145 ng/ml for DHT. 
*Plasma DHT levels of GDX + DHT animals were significantly (p< .01) higher 
than in intact animals. 
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Figure 14. Hybridization density of a 35S-labelled oligonucleotide probe 
complementary to nucleotides 496-543 of rat CRH mRNA in the paraventricular 
nucleus (PVN) of male F344 rats. Animals were either intact {INT), were bilaterally 
gonadectomized under ether anesthesia, or were adrenalectomized (ADX). 
Gonadectomized animals received either DHT using a 2.5 cm Silastic capsule 
subcutaneously implanted in each animal's back (GDX + DHT) or a sham operation 
(GDX). GDX and GDX+DHT animals were sacrificed by decapitation 21 days after 
surgery. ADX animals were sacrificed 7 days after surgery. * designates groups 
which are significantly different from intact group (p < .05). 
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Figure 15. Numbers of cells in the dorsal medial parvocellular (PVNmpd), dorsal 
parvocellular (PVNdp), and ventral medial parvocellular (PVNmpv) subdivisions of the 
hypothalamic paraventricular nucleus radiolabelled using a 35S-labelled oligonucleotide 
probe complementary to nucleotides 496-543 of rat CRH mRNA. Animals were 
either intact (INT), were bilaterally gonadectomized under ether anesthesia, or were 
adrenalectomized (ADX). Gonadectomized animals received either DHT using a 2.5 
cm Silastic capsule subcutaneously implanted in each animal's back (GDX + DHT) or 
a sham operation (GDX). GDX and GDX + DHT animals were sacrificed by 
decapitation 21 days after surgery. ADX animals were sacrificed 7 days after 
surgery. * designates groups which are significantly different from intact group 
(p< .01). n=3-6. 
Figure 16. Darkfield photomicrographs demonstrating CRH mRNA hybridization 
over the paraventricular nucleus of the hypothalamus of intact (A), gonadectomized 
(B), and adrenalectomized (C) male rats. Animals were gonadectomized 3 weeks 
prior to sacrifice. Adrenalectomized animals were sacrificed 7 days after surgery. 
Bar= 100 µm. 
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shows the number of cells positively labelled for CRH mRNA in three regions of the 
PVN of INT, GDX, GDX+DHT, and ADX male rats. There were significantly 
more (p< .01) CRH mRNA-labeled cells in the dorsal medial parvocellular 
subdivision of the PVN (PVNmpd) in ADX animals compared to intact rats. However, 
in the PVNmpd the numbers of CRH mRNA-labelled cells in INT, GDX, 
andGDX + DHT animals were not significantly different. In addition, the numbers of 
CRH mRNA-labelled cells in the dorsal parvocellular (PVNdp) and ventral medial 
parvocellular (PVNmpv) subdivisions did not significantly differ among the treatment 
groups. Photomicrographs of representative frontal sections demonstrating CRH 
mRNA expressing cells in the PVN of INT, GDX, and ADX male rats are shown in 
Figure 16. 
The hybridization density of a 35S-labelled oligonucleotide probe for A VP 
mRNA in the PVN of INT, GDX, GDX + DHT, and ADX animals is shown in 
Figure 17. There were no significant differences in hybridization density in the PVN 
among the treatment groups. However, the area hybridized was significantly greater 
(p< .05) in ADX animals compared to intact animals (INT, 1.03 + 0.07 mm2; ADX, 
1.88 + 0.27 mm2). The numbers of cells positively labelled for A VP mRNA in the 
magnocellular (PVNM) and parvocellular (PVNp) subdivisions of the PVN of INT, 
GDX, GDX+DHT, and ADX male rats are shown in Figure 18. There were 
significantly (p < . 01) more radiolabelled cells in the parvocellular, but not the 
magnocellular, subdivision of the PVN in ADX animals compared to INT animals. 
However, there were no significant differences in numbers of radiolabelled cells 
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Figure 17. Hybridization density of a 35S-labelled oligonucleotide probe 
complementary to nucleotides 286-315 of prepro-AVP mRNA in the paraventricular 
nucleus (PVN) of male F344 rats. Due to the short exposure time for sections 
hybridized with the probe for prepro-AVP mRNA, a standard curve could not be 
generated. Therefore, hybridization density was expressed in optical density (O.D.) 
units. Animals were either intact (INT), bilaterally gonadectomized under ether 
anesthesia, or adrenalectomized (ADX). Gonadectomized animals received DHT 
using a 2.5 cm Silastic capsule subcutaneously implanted in each animal's back 
(GDX + DHT) or a sham operation (GDX). GDX and GDX + DHT animals were 
sacrificed by decapitation 21 days after surgery. Adrenalectomized animals were 
sacrificed 7 days after surgery. It should be noted that the scale for 0.D. units runs 
from 0 to a maximum of 1.0. 
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Figure 18. Numbers of cells in magnocellular (PVNM) and parvocellular (PVNP) 
subdivisions of the paraventricular nucleus of the hypothalamus radiolabelled using a 
35S-labelled oligonucleotide probe complimentary to nucleotides 286-315 of prepro-
AVP mRNA. Male rats were either intact (INT), bilaterally gonadectomized under 
ether anesthesia, or adrenalectomized (ADX). Gonadectomized animals received 
DHT using a 2.5 cm Silastic capsule subcutaneously implanted in each animal's back 
(GDX + DHT) or a sham operation (GDX). GDX and GDX + DHT animals were 
sacrificed by decapitation 21 days after surgery. Adrenalectomized animals were 
sacrificed 7 days after surgery. * designates groups which are significantly different 
from intacts (p< .01). n=3-6. 
Figure 19. Darkfield photomicrographs demonstrating AVP mRNA hybridization 
over the paraventricular nucleus of the hypothalamus of intact (A), gonadectomized 
{B), and adrenalectomized (C) male rats. Animals were gonadectomized 3 weeks 
prior to sacrifice. Adrenalectomized animals were sacrificed 7 days after surgery. 
Bar= 100 µm. 
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Figure 20. Hybridization density of a 35S-labelled oligonucleotide probe 
complementary to nucleotides 496-543 of rat CRH mRNA in the paraventricular 
nucleus (PVN) of male F344 rats. Animals were either intact (INT) or were 
bilaterally gonadectomized under ether anesthesia. Gonadectomized animals received 
DHT using a 2.5 cm Silastic capsule subcutaneously implanted in each animal's back 
(GDX+DHT1()d) or a sham operation (GDX1()d). Animals were sacrificed by. 
decapitation 10 days after surgery. n=6. 
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Figure 21. Numbers of cells in the dorsal medial parvocellular (PVNmpd), dorsal 
parvocellular (PVNdp), and ventral medial parvocellular (PVNmpv) subdivisions of the 
hypothalamic paraventricular nucleus radiolabelled using a 35S-labeled oligonucleotide 
probe complementary to nucleotides 496-543 of rat CRH mRNA. Animals were 
either intact (INT) or were bilaterally gonadectomized under ether anesthesia. 
Gonadectomized animals received DHT using a 2.5 cm Silastic capsule 
subcutaneously implanted in each animal's back (GDX + DHT) or a sham operation 
(GDX). Animals were sacrificed by decapitation 10 days after surgery. n=4-6. 
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among INT, GDX, and GDX + DHT rats. Photomicrographs of representative frontal 
sections showing A VP mRNA expressing cells in the PVN of INT, GDX, and ADX 
male rats are shown in Figure 19. 
Figure 20 shows the hybridization density of the 35S-labelled oligonucleotide 
probe for CRH mRNA in the PVN of intact male rats (INT), male rats that have been 
castrated for 10 days (GDX10d), and rats that have been castrated and DHT-treated for 
10 days (GDX+DHT10d). There were no significant differences in 
hybridizationdensity among these treatment groups. The numbers of cells positively 
labelled for CRH mRNA in three subdivisions of the PVN (PVNmpd' PVNdP' and 
PVNmpv) of INT, GDX10d, and GDX + DHT IOd are shown in Figure 21. The number 
of radiolabelled cells did not significantly differ among the treatment groups in any of 
the three subdivisions. 
Discussion 
Previous studies suggest that circulating androgens inhibit the activity of the 
HPA axis (Critchlow et al., 1963; Gaskin and Kitay, 1971; Viau and Meaney, 1991b; 
Handa et al., 1994). For example, the ACTH and corticosterone responses to 
footshock or novel environment stress are increased in male rats three weeks after 
gonadectomy (Handa et al., 1994). Furthermore, treatment of gonadectomized males 
with testosterone or the non-aromatizable androgen, DHT, normalizes the ACTH and 
corticosterone responses to these stressors. The regulation of the HPA axis by 
circulating androgens appears to occur, at least in part, at the level of the 
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byp<>thaiamus. Hypothalamic CRH content is increased three weeks after castration in 
male rats (Bingaman, et al., 1994). 
The results of the present study indicate that CRH mRNA levels and the 
number of CRH mRNA expressing cells in parvocellular PVN neurons are not altered 
three weeks after castration. This is consistent with a previous study which suggests 
that 7 or 28 days of gonadectomy does not alter CRH mRNA in the PVN (Almeida et 
al., 1992). Thus, the changes observed in hypothalamic CRH content and CRH-
immunoreactive cell numbers in the PVN after gonadectomy of male rats (Bingaman 
et al., 1994) cannot be explained by concurrent changes in CRH mRNA in the PVN. 
Alternatively, androgens could be suppressing the translational efficiency or 
decreasing the half-life of the CRH peptide. 
In contrast, we observed approximately a 60% increase in CRH mRNA levels 
in the PVN seven days after adrenalectomy. Furthermore, adrenalectomy resulted in 
an increase in the number of CRH mRNA expressing cells in the PVNmpd· These 
data are consistent with studies reporting similar increases in CRH mRNA in the PVN 
following adrenalectomy (Young et al., 1986a; Kovacs and Mezey, 1987; Beyer et 
al., 1988; Swanson and Simmons, 1989; Imaki et al., 1991). It has been reported 
that while corticosterone may decrease CRH gene expression in the PVNmpd' high 
levels of corticosterone increase CRH mRNA in the PVNdp and PVNmpv (Swanson 
and Simmons, 1989). In the present study we did not observe a significant difference 
in the number of CRH mRNA expressing cells in the PVNdp or the PVNmpv in 
adrenalectomized animals compared to intact rats. It is possible that the levels of 
cireulating corticosterone in the intact rats are not sufficiently high to achieve a 
significant difference compared to adrenalectomized animals. 
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The effect of gonadectomy and androgen treatment on A VP mRNA levels in 
the PVN were evaluated due to AVP's role as a corticotropin-releasing factor. The 
data indicate that A VP mRNA levels and the number of A VP mRNA expressing cells 
are also not altered three weeks after gonadectomy. Adrenalectomized animals were 
again used as a positive control. The number of A VP mRNA expressing cells was 
significantly increased in parvocellular PVN neurons of adrenalectomized rats 
compared to intact animals. These data are consistent with previous studies (Young et 
al., 1986b; Swanson and Simmons, 1989). 
It is not surprising that circulating androgens had no effect on A VP gene 
expression. It was previously reported that gonadectomy of male rats did not lead to 
changes in AVP immunoreactivity in the PVN (DeVries et al., 1985; Bingaman et 
al., 1994). Although it is clear that androgens regulate AVP-immunoreactivity and 
A VP mRNA levels in the bed nucleus of the stria terminalis and medial amygdala 
(De Vries et al., 1985; Miller et al., 1992), androgens do not appear to influence AVP 
gene expression in the PVN. 
Previously, it was reported that hypothalamic CRH content begins to rise 10 
days after gonadectomy of male rats (Bingaman et al. , 1994). It is possible that CRH 
synthesis may increase briefly in the castrate and then return to steady state once the 
larger CRH pool is established. If this were the case, this transient increase would be 
expected to precede changes in protein content. However, in the present study CRH 
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JDRNA levels in the PVN were not altered 10 days after gonadectomy. This suggests 
that the increase in hypothalamic CRH content following gonadectomy (Bingaman et 
al., 1994) is not the result of a transient increase in CRH gene expression. A small 
increase in the number of CRH mRNA expressing cells was observed in the PVNmpd 
10 days after gonadectomy. This increase was not, however, statistically significant. 
Thus, it is possible that there is a transient increase in CRH gene expression and that 
this change occurs in a small subset of cells such that the effect is masked using the 
analysis techniques employed in this study. It is also possible that 10 days after 
gonadectomy is not the optimum time point to observe such a transient change in 
CRH gene expression. 
In summary, the results of this study suggest that CRH and A VP mRNA levels 
in the PVN are not affected by circulating androgens. Thus, previously reported 
changes in hypothalamic CRH content and CRH-immunoreactive cell numbers in the 
PVN after gonadectomy cannot be explained by changes in CRH gene expression. It 
is possible that circulating gonadal androgens alter hypothalamic CRH content by 
altering CRH translational efficiency or peptide half-life. In addition, it should be 
noted that it is not known whether androgens act directly on the PVN to affect 
changes in CRH content. There may exist a complex pathway by which circulating 
androgens regulate CRH neurons and thus, the HPA axis. 
CHAYfER V 
LOCALIZATION OF ANDROGEN RECEYfOR-IMMUNOREACTIVITY 
WITHIN PEPIIDERGIC NEURONS OF THE RAT BRAIN 
Summary 
This study tested for the presence of androgen receptor immunoreactivity in 
somatostatin, galanin, vasopressin, corticotropin-releasing hormone, and oxytocin 
neurons in the rat forebrain. The brains of adult male Sprague/Dawley rats were 
fixed with 4 % paraformaldehyde. Androgen receptor was visualized in coronal 
sections using nickel intensification of diaminobenzidine, and the neuropeptides were 
identified using a brown diaminobenzidine reaction product. Androgen receptor was 
localized to the nuclei of neurons in the septum, amygdala, cortex, hippocampus and 
hypothalamus. The majority of somatostatin containing neurons in the periventricular 
hypothalamic nucleus also contained androgen receptor. Androgen receptor was also 
found within galanin expressing cells in the bed nucleus of the stria terminalis and in 
the amygdala. Androgen receptor was not observed in corticotropin-releasing 
hormone, vasopressin, or oxytocin neurons in any area examined. The data suggest 
that androgens may be capable of directly regulating somatostatin expressing neurons 
of the periventricular nucleus of the hypothalamus and galanin containing neurons of 
the bed nucleus of the stria terminalis and amygdala. 
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Introduction 
The regulation of cellular processes by androgens requires the presence of the 
androgen receptor (AR) which acts as a ligand-responsive transcription factor. The 
distribution of AR in the brains of several species has been described previously 
(Handa et al., 1987; Sar and Stumpf, 1975). In the rat, AR is localized throughout 
many forebrain regions including the septum, amygdala, cortex, hippocampus, and 
hypothalamus. This distribution overlaps that of many neuropeptide transmitters and 
hormones. 
Several recent studies have examined the regulation of neuropeptides by 
androgens. Somatostatin (Gross, 1980) and somatostatin mRNA (Argente et al., 
1990; Werner et al., 1988) in hypothalamic neurons are increased by testosterone 
providing one mechanism through which androgens may control growth hormone 
secretory patterns. Vasopressin (AVP) immunoreactivity (DeVries et al., 1985; 
Miller et al., 1992), A VP mRNA (Miller et al., 1992), and galanin mRNA (Miller et 
al., 1993a) are decreased in the bed nucleus of the stria terminalis (BNST) by long-
term castration. Recent evidence also suggests that androgens suppress corticotropin-
releasing hormone (CRH) immunoreactivity in the hypothalamic paraventricular 
nucleus (Almeida et al., 1992; Bingaman et al., 1994) thereby influencing the 
hypothalamo-pituitary-adrenal response to stress. These neuropeptide systems provide 
an opportunity to examine androgen receptor-mediated regulation of chemically 
identified neurons. 
It is currently unknown whether androgens are capable of directly regulating 
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forebrain neuropeptide transmitters. In order for this to occur, AR must be expressed 
within neuropeptide containing cells of the central nervous system, and an androgen 
response element should be present upstream of the neuropeptide gene. The 
following experiment tested for the presence of AR immunoreactivity within 
somatostatin, galanin, A VP, CRH, and oxytocin neurons in the rat forebrain. 
Materials and Methods 
Six adult male Sprague/Dawley rats (250-275 g) were given a lethal dose of 
sodium pentobarbital and perfused through the ascending aorta with 4 % 
paraformaldehyde. Brains were removed and post-fixed overnight in 
paraf ormaldehyde. 30 µm-thick coronal sections were cut through the diencephalon 
on a vibratome (Technical Products Intl., St. Louis, MO). Androgen receptor 
immunoreactivity was visualized using an immunoaffinity purified rabbit polyclonal 
antibody to rat/human androgen receptor (Prins et al., 1991). This antibody was 
generated using a synthetic peptide corresponding to amino acids 1-21 of AR and was 
the generous gift of Dr. Gail S. Prins (Department of Obstetrics & Gynecology, 
Univ. of Illinois College of Medicine, Chicago, IL). Free-floating sections were 
incubated with antiserum diluted at 0.5 ug/ml in 0.1 M phosphate buffered saline 
(PBS) with 0.25% Triton X-100 (Malinkrodt, Paris, KY) and 2% normal donkey 
serum for 18-24 hours at 4°C. Sections were incubated with biotinylated donkey anti-
rabbit gamma-globulin (1:250; Jackson Immunoresearch, West Grove, PA) and then 
in streptavidin-horseradish peroxidase (Vector, Burlington, CA). Nickel ammonium 
98 
sulfate (25 mg/ml) intensified diaminobenzidine (DAB) was used as the chromagen 
yielding black-stained cell nuclei. Following the immunohistochemical reaction for 
AR-IR cells, sections were washed in PBS with 0.25% Triton X-100 for 38-42 hours 
at 4°C. 
The following primary antisera were used for the immunohistochemical 
detection of neuropeptides: anti-corticotropin-releasing hormone (lot #465) provided 
by the late Dr. T.L. O'Donohue, anti-arginine vasopressin (48 bleed 10) and anti-
oxytocin (45 bleed 10) provided by Dr. S.J. Watson (Univ. of Michigan, Ann Arbor), 
anti-galanin obtained from Peninsula Labs (San Carlos, CA, RAS-7153N, lot# 
006807), and anti-somatostatin obtained from Incstar (Stillwater, MN, lot# 853027). 
After washing the sections stained for AR-IR, these sections were incubated with 
antiserum diluted at either 1: 1000 (galanin and somatostatin), 1:2000 (CRH), or 
1:10,000 (AVP and oxytocin) in O.lM PBS with .25% Triton X-100 and 2% normal 
donkey serum for 18-24 hours at 4°C. Immunoreactivity was visualized using a 
biotinylated secondary antibody, streptavidin-horseradish peroxidase, DAB complex as 
described above except that nickel ammonium sulfate was not present. Sections were 
mounted on gel-coated slides. 
To verify specificity of AR antibody immunostaining, the AR antibody was 
preincubated with either the peptide used to generate the AR antibody or a distant 
peptide prior to exposure to the tissue. The peptide used to generate the antibody 
(peptide 1-21) competed off specific signal. The distant peptide (peptide 462-4 78) had 
no effect on AR-IR. As a control for neuropeptide antisera specificity, 1 ml of each 
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diluted antiserum was preincubated with 50 µg of its respective synthetic 
neuropeptide, and the sections were processed as usual to determine whether any 
residual staining remained. Specific immunohistochemical staining was not observed 
in these controls. However, it is still possible that these antisera may recognize 
unidentified antigens containing similar amino acid sequences. Thus, the 
immunoreactivity detected in this study is more accurately described as AR-like and 
neuropeptide-like immunoreactivity. 
Peptide-IR cells were identified by the presence of brown cytoplasmic 
immunohistological staining. Cells were considered to be AR-IR if a dark-stained 
nucleus was discernable. Neurons containing AR-IR and peptide-IR (i.e. double-
labelled cells) exhibited a dark-stained nucleus surrounded by a brown cytoplasm. 
AR-, peptide-, and double-labelled cells were counted throughout nuclei in which 
colocalization was observed. Every fourth section was sampled and used for 
evaluation of AR-IR in conjunction with the immunoreactivity of a single peptide. 
Results 
The distribution of AR-IR was similar to the distribution of AR previously 
described (Sar and Stumpf, 1975; Handa et al., 1987; Wood and Newman, 1993). 
AR-IR was abundant in the lateral septum, BNST, medial preoptic area, ventromedial 
and arcuate nuclei of the hypothalamus, CAl region of the hippocampus, amygdala, 
and cortex. AR staining was localized predominantly in cell nuclei. The distribution 
of somatostatin, galanin, A VP, CRH, and oxytocin overlapped that of AR in many 
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forebrain regions examined. 
AR was found within somatostatin containing neurons of the periventricular 
nucleus of the hypothalamus adjacent to the third ventricle (figure 22 A,B). In the 
periventricular nucleus, double-stained cells represented 78.7+6.4 % of somatostatin-
IR neurons and 54.6+9.8% of AR-IR neurons {n=3). A few somatostatin containing 
cells in the paraventricular nucleus of the hypothalamus also expressed AR. 
AR-IR was also found within galanin containing cells in the BNST (figure 22 
C,D) and the medial and central amygdaloid nuclei. In the BNST double-stained cells 
represented 39.0+4.9% of galanin-IR and 1.1 +0.4% of AR-IR neurons {n=3). In 
the medial amygdala, 44.0 % of galanin expressing cells also expressed AR while 
1.25 % of AR-IR cells also contained galanin {n=2). In the central nucleus of the 
amygdala, double-stained cells represented 23 .1 % of galanin cells and 1. 3 % of AR-IR 
neurons {n=2). 
Nuclear staining was not observed in somatostatin- and galanin-IR cells in 
areas that did not show AR-IR. For example, nuclear staining was not observed in 
somatostatin-IR neurons of the caudate putamen. Similarly, brown cytoplasmic 
staining was not seen in areas where AR-IR, but not somatostatin- or galanin-IR cells, 
are found (e.g. the ventromedial hypothalamus). 
AR was not found in CRH (figure 22 E,F), AVP, or oxytocin neurons in the 
hypothalamus, septum, BNST, or amygdala. 
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Figure 22. Brightfield photomicrographs showing localization of androgen receptor 
immunoreactivity within somatostatin containing neurons in the periventricular nucleus 
of the hypothalamus (A, B), localization of androgen receptor immunoreactivity 
within galanin expressing neurons in the bed nucleus of the stria terminalis (C, D), 
and the distribution of androgen receptor immunoreactivity and corticotropin-releasing 
hormone (CRH) immunoreactivity in the paraventricular nucleus of the hypothalamus 
(E, F). Androgen receptor immunoreactivity was visualized using nickel intensified 
diaminobenzidine yielding a black reaction product within cell nuclei (open arrows). 
Somatostatin (A,B), galanin (C,D), and CRH (E,F) immunoreactivity was visualized 
as a brown diaminobenzidine reaction product present in the cell cytoplasm (solid 
arrows). Examples of double-stained cells are indicated with an asterisk(*). 
3V=third ventricle. Bar indicates either 500 µm (A,C), 250 µm (E), or 50 µm 
(B,D,F). 
A 
c 
. .. . . . 
.... · 
. ·' -
' 
3V 
' , 
~ 
•• 
~ 
. ~· 
. , . .,,. 
·- . . 
• 
• 
' . J 
i 
~ . 
• 
.. 
• 
102 
3V 
*-~' · 
.. .. .. 
·• 
• 
. ::> .. .. , 
• • 
··~-. ... · T. . 
,, . - ,., . 
• 
103 
Discussion 
These data demonstrate that AR is localized within somatostatin expressing 
cells of the periventricular nucleus of the hypothalamus. Cells in this region project 
to the median eminence where somatostatin acts as the major inhibitor of growth 
hormone secretion from the anterior pituitary (Brazeau et al., 1973). Previous studies 
have demonstrated a sex difference in the secretory patterns of growth hormone (for 
rev. see Jansson et al., 1985). Growth hormone secretion is influenced by circulating 
gonadal steroids such that both stimulatory (growth hormone-releasing hormone, 
GHRH) and inhibitory (somatostatin) inputs to pituitary growth hormone secretion are 
modulated by gonadal steroids (Gross, 1980; Werner et al., 1988; Chowen-Breed et 
al., 1989; Ulloa-aguirre et al., 1990; Zeitler et al., 1990; DeGennaro et al., 1991; 
Zorilla et al., 1991). Although steroid regulation of growth hormone secretion has 
yet to be completely defined, it is clear that androgens increase somatostatin mRNA 
in the periventricular nucleus (Argente et al., 1990; Werner et al., 1988) through an 
androgen receptor-mediated processes (Argente et al., 1990). Our data suggest that 
androgens may act within hypothalamic somatostatin expressing neurons to alter 
somatostatin gene expression. 
We have demonstrated that AR is localized with galanin in neurons in the 
BNST and amygdala. This is consistent with a recent report that androgen regulates 
galanin gene expression in the BNST (Miller et al., 1993a) and suggests that 
androgens act within galanin cells of the BNST. Although the function of galanin in 
the BNST is unknown, the majority of A VP neurons in this region express galanin 
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rnRNA (Miller et al., 1993b). It has been suggested that a potential role for galanin 
in these neurons may involve the presynaptic modulation of co-released vasopressin 
(Miller et al., 1993b). Interestingly, we report here that AR-IR was not localized 
within AVP-IR neurons in any region examined. This contradicts a recent report that 
AR immunoreactivity is localized within A VP cells of the BNST and MeA (Zhou et 
al., 1994). However, the Zhou study as well as previous reports of androgen 
regulation of AVP immunoreactivity (De Vries et al., 1985; Miller et al., 1992) 
involved the use of colchicine to demonstrate A VP-IR in the BNST and medial 
amygdala. In this study, we did not use colchicine and thus saw very few AVP-IR 
cells in the BNST and medial amygdala. The possibility remains that the AR-
IR/galanin cells we observed in the BNST and medial amygdala may express A VP but 
would only display AVP-IR upon prior treatment with colchicine. 
Recent studies suggest that androgens play a role in the regulation of the 
neuroendocrine stress response (Handa et al., 1994). Hypothalamic CRH content and 
CRH-IR in the paraventricular nucleus are decreased by androgens (Bingaman et al., 
1994). However, the absence of AR in the CRH containing cells throughout the 
paraventricular nucleus suggests that androgens influence CRH neurons via a 
transsynaptic mechanism. The data also suggest that androgens do not influence the 
hypothalamo-pituitary-adrenal response to stress through direct actions on oxytocin or 
AVP cells of the paraventricular nucleus. AR-IR was not found within AVP or 
oxytocin expressing neurons in any subregion of the parvocellular or magnocellular 
paraventricular nucleus. 
105 
In summary, we have used a dual immunohistochemical technique to determine 
whether neuropeptide containing cells contain the intracellular machinery to be 
directly regulated by androgens. Using this technique, AR-IR was found within 
somatostatin expressing cells of the hypothalamic periventricular nucleus and galanin 
expressing cells of the BNST and amygdala. Colocalization of AR-IR and AVP, 
CRH, or oxytocin was not observed in neurons of the rat forebrain. In light of the 
fact that colchicine was not used in this study, the possibility exists that AR-IR was 
not observed in A VP, CRH, or oxytocin containing neurons because some cell groups 
that express these peptides may not have been stained. This double 
immunohistochemical staining technique is a valuable tool in characterizing AR 
containing cells. However, the great majority of AR containing cells in many limbic 
brain areas have yet to be characterized in terms of transmitter phenotype. 
CHAYfER VI 
DIFFERENTIAL EFFECTS OF CIRCULATING ANDROGEN ON 
NEUROENDOCRINE AND BEHAVIORAL RESPONSES 
TO CONDIDONAL STRESS 
Summary 
The purpose of this study was to examine the effect of circulating androgens 
on neuroendocrine, autonomic, and behavioral responses to stress. In rats stress 
produces increases in plasma ACTH, corticosterone, prolactin, and renin, increases in 
defecation, and characteristic behavioral changes. Androgens may play an important 
role in the expression of these responses. The effects of conditioned stress were 
studied in male Sprague/Dawley rats that were gonadectomized with or without 
dihydrotestosterone (DHT) treatment or received sham surgeries. Animals were 
stressed three weeks after surgery. The ACTH response to conditioned stress was 
significantly potentiated (p< .01) in gonadectomized males compared to sham-
operated and gonadectomized, DHT-treated animals. In stressed rats, plasma 
corticosterone levels were significantly higher (p < .05) in gonadectomized animals 
compared to DHT-treated castrates. The prolactin response to stress was decreased 
(p< .01) in gonadectomized males compared to sham and gonadectomized, DHT-
treated rats. The stress-induced increases in plasma renin activity and concentration 
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were not altered by gonadectomy or DHT. Non-stressed DHT-treated castrates 
exhibited more "fear-like" behavior (e.g., more freezing and less sniffing) compared 
to non-stressed sham and gonadectomized animals. However, conditioned stress 
produced the same behavioral effects in all treatment groups. The results demonstrate 
that the ACTH/corticosterone, prolactin, and behavioral responses to a psychological 
stressor are differentially regulated by circulating androgens. 
Introduction 
Aversive or anxiogenic stimuli cause biological changes that have been termed 
the stress response. This so-called stress response is characterized by well 
documented neuroendocrine, autonomic, and behavioral reactions that serve to 
preserve the integrity of the animal. Almost all forms of stress produce increases in 
plasma adrenocorticotropic hormone (ACTH), corticosterone, prolactin, and renin (for 
rev. see Van de Kar et al., 1991). Enhanced release of corticosterone and ACTH 
reflects activation of the hypothalamo-pituitary-adrenal axis. Prolactin release is 
regarded as a reliable index of the stress response, although the physiological 
significance of prolactin release during stress is unclear. Stress-induced release of 
renin from the kidney indicates that the renin-angiotensin system is stimulated. The 
renin-angiotensin system plays an essential role in the regulation of blood pressure 
and electrolyte balance (Imagana et al., 1984; Churchill et al., 1978). In most 
species anxiogenic stimuli cause increases in defecation suggesting altered autonomic 
output to the gastrointestinal system (Miyata et al., 1992). Behavioral indicators of 
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streSS in the rat include an increase in freezing and a decrease in rearing, grooming, 
sniffing, and locomotor activities (e.g., Rittenhouse et al., 1992; Britton et al., 1982). 
A limited number of studies have examined the effects of gonadal steroids on 
the stress response. A sex difference in basal corticosterone titers and in the 
corticosterone response to ether stress has been reported (Kitay, 1961). Females have 
higher basal corticosterone levels and enhanced corticosterone responses to stress 
compared to males. Several studies suggest that this sex difference arises, in part, as 
a result of estrogen acting to enhance hypothalamo-pituitary-adrenal activity (Kitay, 
1963; Viau and Meaney, 1991a; Burgess and Handa, 1992). Conversely, circulating 
androgens appear to inhibit ACTH and corticosterone responses to stress. 
Gonadectomized male rats exhibit enhanced corticosterone and ACTH responses to 
foot shock and open field stressors (Handa et al., 1994). Treatment of 
gonadectomized rats with testosterone or the non-aromatizable androgen, 
dihydrotestosterone (DHT}, normalizes the ACTH and corticosterone responses to 
these stressors. Furthermore, in male rats the magnitude of the corticosterone 
response to immobilization is negatively correlated with the levels of circulating 
testosterone (Viau and Meaney, 199lb). 
As noted above, most studies investigating the effect of gonadal hormones on 
the stress response have sampled only one or two parameters of the stress response. 
In the following experiment we examined the effects of circulating androgens on 
neuroendocrine, autonomic, and behavioral indices of stress. It is important to 
determine whether androgens selectively or globally modulate the expression of 
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various parameters of the stress response. The effects of conditioned stress were 
examined in male rats that were gonadectomized or gonadectomized and treated with 
dihydrotestosterone. We tested whether gonadal androgens alter the corticosterone 
and ACTH responses to conditioned stress as has been shown to occur in response to 
footshock and open field stressors (Handa et al. , 1994). The effect of androgens on 
stress-induced increases in plasma prolactin, renin concentration, and renin activity 
also were examined. In addition, this experiment examined the influence of 
androgens on the stress-induced changes in defecation and several behavioral 
parameters associated with fear or anxiety. 
Materials and Methods 
Animals 
Male Sprague/Dawley rats (200-250 g) were purchased from Harlan 
(Indianapolis, IN). Sprague/Dawley rats were used rather than Fischer 344 (F344) 
rats due to the great amount of animal handling inherent to the conditioning 
procedure. It is difficult to achieve very low baseline hormone levels in control 
animals using the inbred F344 strain. Animals were housed, 2 per cage, in 
temperature (22-24°C) and humidity (50-55 % ) controlled rooms. Animals were kept 
on a 12: 12 h light: dark cycle with lights on at 0700h. Food and water were available 
ad libitum. All experimental protocols were approved by Loyola University Animal 
Care and Use Committee, and were conducted according to the NIH Guide for the 
Care and Use of Laboratory Animals. 
110 
&Jrgro 
Animals were bilaterally gonadectomized under halothane anesthesia. One half 
of the gonadectomized animals were administered dihydrotestosterone (DHT) via a 
2.5 cm Silastic capsule containing crystalline DHT propionate subcutaneously 
implanted in each animal's back (GDX + DHT). The remainder of the 
gonadectomized animals received a sham incision (GDX). Control animals received 
the same surgeries except that the gonads were not removed and capsules were not 
implanted in their backs (SHAM). 
Conditioned Stress Paradigm 
Training and testing were conducted in a rectangular chamber with a grid floor 
composed of stainless steel rods (7.6 mm in diameter) spaced 12.7 mm apart. The 
walls and ceilings of the apparatus were made of Plexiglas and illuminated by a 20-
watt fluorescent lamp. The chamber was located inside a sound-proof box equipped 
with a one-way mirror so that the animal's behavior could be videotaped. Scrambled 
current shock was delivered through the grid floor. 
Rats were randomly assigned to treatment groups (control versus stress). Cage 
mates received the same treatment. Cage mates were tested sequentially and at the 
same time of day (between 10:00 and 13:30 h) on 4 consecutive days. All rats were 
handled 2 minutes/day on each of 4 consecutive days prior to training. Training was 
begun 18 days after surgery. On each of 4 consecutive days, the rats were 
transported to the conditioning chamber in a transfer cage identical to their home 
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cage. The rats remained for 5 minutes in the transfer cage prior to placement in the 
conditioning chamber. For the first 3 days, the experimental (stressed) animals 
received a 10 sec inescapable foot shock (0.8 mA) that was initiated ten minutes 
following placement in the chamber. Control rats were treated identically except that 
they were never shocked. The rats were then returned to their home cage. On the 
fourth day, animals were placed in the test chamber for 10 minutes but did not 
receive a foot shock. At the end of the 10 minutes, the rats were removed, 
transported to an adjacent room and killed by decapitation. Trunk blood was 
collected for hormone analysis into tubes containing 0.5 ml of 0.3 M EDTA, pH 7.4. 
Plasma samples were stored at -7CJ'C until assayed for various hormones. On the 
fourth day, the fecal boli in the test chamber were counted after the removal of each 
animal. In addition, animals were video-recorded during their final 10-minute 
interval in the test chamber. Later, videotapes were viewed, and the duration and 
frequency of freezing, sniffing, grooming, rearing, and locomotor behaviors were 
scored using a computer program developed by Dr. Andrew D. Levy in the 
laboratory of Dr. Louis D. Van de Kar (Loyola University, Dept. of Pharmacol. and 
Exp. Ther.). 
Biochemical Determinations 
Plasma conicosterone and ACTH assays were performed on unextracted 
plasma samples according to standard laboratory procedures as previously described 
in detail (Lorens and Van de Kar, 1987; Carnes et al., 1986). Corticosterone was 
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assayed using antiserum from ICN Biomedicals, Inc. (Casa Mesa, CA). Data were 
analyzed by the computer program RIA-AID (Robert Maciel Assoc., Arlington, MA). 
The sensitivity was 0.01 ng/tube, and the intra-assay variance was 4.5%. For 
measurement of this and all subsequent hormones all values were obtained in one 
assay to avoid inter-assay variance. The ACTH antiserum was purchased from IgG 
Corp. (Nashville, TN). The ACTH antibody recognizes amino acids 5-18. The 
antibody does not recognize a-MSH, P-endorphin, P-lipotropin, ACTH 1-24 or 
ACTH 1-16 amide. The ACTH for standards (1-39) was obtained from Calbiochem 
and 1251-labelled ACTH was obtained from Incstar (Stillwater, MN). The sensitivity 
of the ACTH assay was 0.25 pg/tube, and the intra-assay variance was 4.2 % . 
Prolactin radioimmunoassay (RIA) was performed with reagents provided by 
the NIADDK. Anti-rat prolactin serum S-9 was used at a dilution of 1:25,500 as 
described previously (Van de Kar and Bethea, 1982). The standards were made from 
the rat prolactin reference preparation NIADDK-rprl-RP-3. Anti-rabbit IgG 
(Calbiochem, San Diego, CA) was used to separate the free from the bound tracer. 
The sensitivity of the assay was 0.02 ng/tube, and the intra-assay variability was 
4.8%. 
Plasma renin activity was measured using a RIA for generated angiotensin I 
(ANG I) as described previously (Richardson-Morton et al., 1989). For the assay of 
plasma renin concentration, a saturating concentration of exogenous renin substrate 
(angiotensinogen) was incubated with plasma renin to generate ANG I at maximal 
velocity. Plasma renin substrate was obtained from rats that were nephrectomized 
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and received a dexamethasone injection (0.2 mg/rat) 24 h before sacrifice. The 
procedure was described previously in detail (Richardson-Morton et al., 1989). RIA 
of ANG I was conducted with antiserum produced in our laboratory (Richardson-
Morton et al., 1989). The dilution of antiserum was 1: 16,000. The RIA sensitivity 
limit was 13.5 pg ANG I/tube. The intra-assay variability was 4.4%. 
Plasma testosterone levels were evaluated by RIA using a 125I-testosterone kit 
(ICN Biomedicals, Inc., Casa Mesa, CA). The standard curve ranged from 5 to 500 
pg/tube. Bound and free steroid were separated using a goat anti-rabbit gamma-
globulin. The RIA sensitivity limit was 43 pg/tube. The intra-assay coefficient of 
variance was 5 .1 % • 
For plasma DHT determination, steroids were extracted from samples using 
hexane:ethyl acetate (3:2) and separated on microcelite columns (ICN Biomedicals, 
Inc.) using an isooctane-ethyl acetate system. DHT was eluted from the column with 
5% ethyl acetate in isooctane. Recovery of DHT was 75.9 + 1.3%. Plasma DHT 
was determined by RIA using a 3H-dihydrotestosterone RIA kit (ICN Biomedicals, 
Inc.). The standard curve ranged from 10 to 500 pg/tube. Bound and free steroid 
were separated using dextran-coated charcoal. The RIA sensitivity limit was 49 
pg/tube. The intra-assay coefficient of variance was 7 .5 % . 
Statistics 
The data are represented as the group means and the standard errors of the 
mean (S.E.M.). Data were analyzed by two-way analysis of variance across the two 
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treatments (androgen status x stress/control), and Newman-Keuls' test was used for 
post hoc analysis (Winer, 1977) using a computer program (NWA STATPAK, 
Portland, OR). Plasma testosterone and DHT levels were analyzed by a two-tailed t-
test (Winer, 1977). A p value of < 0.05 was considered significant. 
Results 
Plasma testosterone and DHT concentrations are shown in Table 5. 
Gonadectomy reduced circulating testosterone, and hormone treatment increased DHT 
titers. 
Plasma ACTH concentration was significantly elevated (p < .01) in all 
conditioned stress groups compared to the corresponding non-stressed control groups 
(Figure 23A). In GDX animals, the plasma ACTH levels following conditioned stress 
were significantly greater (p < .01) than in stressed intact (i.e. sham) animals. The 
ACTH response to conditioned stress in DHT-treated castrates did not differ from that 
of sham animals. Corticosterone levels were increased in all conditioned stress 
groups compared to non-stressed control groups (Figure 23B). The increases were 
statistically significant (p < .01) in the GDX and sham groups. The statistical analysis 
indicated that no significant surgery x stress interaction occurred (F2,37 =2.05, 
p<0.14). However, a post hoc Newman Keuls' test revealed that following 
conditioned stress, plasma corticosterone levels were significantly increased (p< .05) 
in GDX male rats as compared to DHT-treated castrates. There were no significant 
differences in plasma ACTH and corticosterone among the treatment groups i11 non-
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Table 5. Plasma testosterone and dihydrotestosterone (DHT) levels in sham, 
gonadectomized, and gonadectomized, DHT-treated male Sprague/Dawley rats 
determined by radioimmunoassay. • Animals were either conditioned stressed or were 
non-stressed controls. 
Testosterone (n)C·d 
SHAM/CONTROL 1.0 + 0.2 (6) 0.36 + .04 (8) 
SHAM/STRESS 2.4 + 0.3 {7)e* 0.49 + .05 (8) 
GDX/CONTROL ND (8) 0.45 + .05 (8) 
GD XI STRESS ND (8) 0.43 + .03 (7) 
GDX + DHT/CONTROL ND (8) 0.95 + .07 (8l# 
GDX + DHT/STRESS ND (8) 0.97 + .06 (8)f# 
•Animals were gonadectomized 3 weeks prior to sacrifice. DHT was administered at 
the time of gonadectomy using a 2.5 cm Silastic capsule containing crystalline DHT 
propionate implanted under the skin of each animal's back. 
bSHAM, sham-operated; GDX, gonadectomized; GDX + DHT, gonadectomized, 
DHT-treated; CONTROL, non-stressed control; STRESS, conditioned stressed 
'Values expressed in ng/ ml 
dn, number of animals per group 
eplasma testosterone levels of SHAM/STRESS animals may be significantly higher 
than those of SHAM/CONTROL rats due to cross-reactivity of the testosterone 
antibody with corticosterone. 
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tnie measured levels of plasma DHT may reflect cross-reactivity of the DHT 
antibody with corticosterone. Also, the levels of plasma DHT measured in SHAM 
and GDX animals were very near the limit of detectability and therefore may not be 
reliable. 
ND designates values too low to detect. The assay limits of detectability were 0.86 
ng/ml for testosterone and 0.22 ng/ml for DHT. 
* Plasma testosterone levels of SHAM/STRESS animals were significantly (p < .01) 
different from SHAM/CONTROL rats. 
# Plasma DHT levels of GDX + DHT/CONTROL and GDX + DHT/STRESS 
animals were significantly (p< .01) different from SHAM/CONTROL and 
SHAM/STRESS animals. 
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Figure 23. Effect of gonadectomy and androgen replacement on plasma ACTH (A) 
and corticosterone (B) concentration in conditioned stress and non-stressed control 
rats. Animals were either sham gonadectomized (SHAM), gonadectomized (GDX), 
or gonadectomized, dihydrotestosterone-treated (GDX + DHT). The data represent 
the mean + the standard error of the mean (S.E.M.) of 7-8 rats per group. 
* designates groups which are significantly different from the corresponding non-
stressed control group (p< .01). #designates groups which are significantly different 
from sham stress and GDX + DHT stress groups (p < .01). @ designates groups 
which are significantly different from the GDX + DHT stress (but not the sham stress) 
group (p < . 05). 
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Figure 24. Effect of gonadectomy and androgen replacement on plasma prolactin 
concentration in conditioned stress and non-stressed control rats. Animals were either 
sham gonadectomized (SHAM), gonadectomized (GDX), or gonadectomized, 
dihydrotestosterone-treated (GDX + DHT). The data represent the mean + the 
standard error of the mean (S.E.M.) of 7-8 rats per group. **designates groups 
which are significantly different from the corresponding non-stressed control group 
(p< .01). *designates groups which are significantly different from the 
corresponding non-stressed control group (p < .05). # designates groups which are 
significantly different from sham stress and GDX + DHT stress groups (p < .01). 
@ designates groups which are significantly different from sham stress group . 
(p< .05). 
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stressed control animals. 
Plasma prolactin concentrations were significantly increased (p< .01) in all 
stress groups compared to non-stressed control groups (Figure 24). The magnitude of 
the stress-induced increase in plasma prolactin concentration was significantly lower 
(p< .01) in castrates than in sham-operated animals and DHT-treated castrates. The 
plasma prolactin concentration following conditioned stress was significantly lower 
(p< .05) in DHT-treated castrates compared to sham-treated animals. 
Plasma renin activity and plasma renin concentration were significantly 
increased (p < . 05) in all conditioned stress groups compared to the corresponding 
non-stressed control groups (Figure 25). Plasma renin activity and concentration were 
not significantly different among the treatment groups in either stressed or unstressed 
animals. 
The number of fecal boli defecated in the chamber during the 10 minute 
testing procedure was increased in all conditioned stress groups compared to non-
stressed control groups (Figure 26). The increases were statistically significant 
(p<.01) in the GDX and GDX+DHT groups. Conditioned stress GDX+DHT rats 
defecated a significantly greater (p < .05) number of boli in the chamber compared to 
stressed sham animals. No significant differences were seen between castrates and 
DHT-treated castrates in either stressed rats or in non-stressed controls. 
The duration of freezing behavior was significantly increased (p < 0.01) in all 
conditioned stressed groups compared to non-stressed control groups (Figure 27). 
Sniffing duration, grooming duration, rearing duration and frequency, and locomotor 
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Figure 25. Effect of gonadectomy and androgen replacement on plasma renin 
activity (A) and plasma renin concentration (B) in conditioned stress and non-stressed 
control rats. Animals were either sham gonadectomized (SHAM), gonadectomized 
(GDX), or gonadectomized, dihydrotestosterone-treated (GDX + DHT). The data 
represent the mean + the standard error of the mean (S.E.M.) of 7-8 rats per group. 
** designates groups which are significantly different from the corresponding non-
stressed control group (p< .01). *designates groups which are significantly different 
from the corresponding non-stressed controls (p< .05). 
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Figure 26. Effect of gonadectomy and androgen replacement on defecation in 
conditioned stress and non-stressed control rats. Animals were either sham 
gonadectomized (SHAM), gonadectomized (GDX), or gonadectomized, 
dihydrotestosterone-treated (GDX + DHT). The data represent the mean + the 
standard error of the mean (S.E.M.) of 7-8 rats per group. *designates groups 
which are significantly different from the corresponding non-stressed control groups 
(p< .01). #designates groups which are significantly different from the sham stress 
group (p < . 05). 
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Figure 27. Effect of gonadectomy and androgen replacement on behavioral 
responses to conditioned stress. The duration (A,B,C,D) and frequency (E,F) of 
freezing (A), sniffing (B), grooming (C), rearing (D,E), and locomotion (F) were 
scored from videotapes of conditioned stress and non-stressed control rats over a 
period of 10 minutes in the testing chamber. Animals were either sham 
gonadectomized (SHAM), gonadectomized (GDX), or gonadectomized, 
dihydrotestosterone-treated (GDX + DHT). The data represent the mean + the 
standard error of the mean (S.E.M.) of 7-8 rats per group. **designates groups 
which are significantly different from the corresponding non-stressed control 
(p<0.01). *designates groups which are significantly different from the 
corresponding non-stressed control (p<0.05). #designates groups which are 
significantly different from sham and GDX non-stressed controls (p < 0.01). 
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@ designates groups which are significantly different from sham non-stressed .controls 
(p<0.05). 
frequency were significantly decreased (p<0.01) in all conditioned stress groups 
compared to non-stressed controls. No differences were seen among the treatment 
groups in animals exposed to conditioned stress. Non-stressed DHT-treated 
castratesexhibited more freezing (p < 0. 01) and less sniffing (p < 0. 01), grooming 
(p<0.05), rearing (p<0.01), and locomotor (p<0.01) activities compared to non-
stressed sham and GDX animals. 
Discussion 
123 
These results indicate that the ACTH and corticosterone responses to 
conditioned stress are increased in castrated male rats. Furthermore, androgen 
treatment normalizes these responses to conditioned stress. This suggests that 
androgens tonically suppress ACTH and corticosterone responses to stress. The data 
are consistent with previous studies which demonstrated that gonadectomy increases 
the ACTH (Coyne and Kitay, 1971; Randa et al., 1994) and corticosterone (Randa et 
al., 1994) responses of male rats to ether (Coyne and Kitay, 1971), footshock (Randa 
et al., 1994) and open field (Randa et al., 1994) stressors. The hypothesis that 
androgens inhibit hypothalamo-pituitary-adrenal responses to stress is further 
supported by data showing that the magnitude of the corticosterone response to 
immobilization is negatively correlated with plasma testosterone titers (Viau and 
Meaney, 1991b). The post-stress plasma corticosterone levels in gonadectomized 
male rats were significantly increased compared to DHT-treated castrates. Following 
stress, plasma corticosterone levels in gonadectomized male rats were increased 
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compared to sham-operated animals, but the effect was not statistically significant. 
The level of plasma DHT in the DHT-treated castrates was significantly higher than 
that of sham-operated male rats (Table 5). Thus, the androgen effect on post-stress 
corticosterone levels could be more apparent in the DHT-treated castrates than in 
sham-operated animals because of the dampening effect of DHT. It is also possible 
that corticosterone levels are still rising and a maximum treatment effect has not yet 
been reached. 
Several possible mechanisms could explain the enhanced corticosterone and 
ACTH responses to stress in the gonadectomized male. Androgens could alter the 
negative feedback of the hypothalamo-pituitary-adrenal axis. However, castrated male 
rats exhibit no changes in either concentration or affinity of glucocorticoid or 
mineralocorticoid receptors in the hippocampus or hypothalamus (Handa et al., 1994). 
Also, anterior pituitary sensitivity to CRH is not altered in gonadectomized male rats 
(Handa et al., 1994). However, hypothalamic CRH content and CRH 
immunoreactivity in the paraventricular nucleus of the hypothalamus are increased in 
gonadectomized male rats (Bingaman et al., 1994). Dihydrotestosterone treatment of 
castrates normalizes hypothalamic CRH. Androgens probably influence hypothalamic 
CRH activity through a transsynaptic mechanism. This is suggested by data showing 
that androgen receptor immunoreactivity is not located within CRH neurons of the 
paraventricular nucleus (Bingaman et al., in press). However, androgen receptors are 
abundant in adjacent regions of the hypothalamus, the limbic system, and the 
brainstem (Handa et al., 1987). Many of these regions are known to provide direct 
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input to the paraventricular nucleus (for rev. see Swanson and Sawchenko, 1983). 
The effect of gonadectomy on the ACTH and corticosterone responses to 
conditioned stress were quite robust. This is important in light of the fact that the 
conditioning paradigm employed in this study involved exposure of the animal to 
stress on 4 consecutive days. Previous studies used only an acute single exposure to a 
stressor (Coyne and Kitay, 1971; Viau and Meaney, 1991b; Handa et al., 1994). 
Thus, the robust effect of androgens observed on the fourth day of exposure to the 
stressor suggests that the effect is functionally important. 
The data indicate that plasma prolactin is dramatically increased in response to 
conditioned stress. The rise in plasma prolactin that occurs in response to conditioned 
stress is significantly attenuated in castrated male rats. This is not completely 
surprising since gonadectomized male rats have decreased basal prolactin titers 
compared to intact animals (Shin et al., 1974; McNeilly et al., 1980; Brar et al., 
1985). Furthermore, administration of testosterone to gonadectomized rats leads to an 
increase in basal circulating prolactin (Shin et al., 1974; Brar et al., 1985; Kalra et 
al., 1973; Weidenbach et al., 1980). In the current study, a small decrease in plasma 
prolactin was observed in control, gonadectomized rats. This decrease was similar in 
magnitude to that reported previously (Brar et al., 1985). Two-way anova showed a 
significant effect of androgens on plasma prolactin. However, post-hoc Newman-
Keuls' analysis did not detect the small change in basal plasma prolactin as 
statistically significant due to the large changes observed in plasma prolactin following 
stress. 
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Pituitary prolactin secretion is under the control of both prolactin-releasing 
factors and a prolactin-inhibiting factor. Many putative prolactin-releasing factors 
have been identified, e.g. vasoactive intestinal polypeptide, thyrotropin-releasing 
hormone, oxytocin, and angiotensin II (for review see Ben-Jonathon et al., 1989). 
The major candidate for a prolactin-inhibiting factor is dopamine (Ben-Jonathon, 
1985). Gonadectomized male rats have an altered episodic pattern of prolactin 
secretion (Grosser and Robaire, 1988) and a decreased pituitary prolactin content 
(Herbert et al., 1977). The pulsatile nature of prolactin secretion is thought to be 
controlled by central mechanisms since the pulsatile plasma prolactin patterns are no 
longer found following sectioning of the pituitary stalk (Wehrenberg and Perin, 
1982). This suggests that circulating androgens influence the central mechanisms 
controlling pituitary prolactin secretion. However, a pituitary site of androgen action 
is still possible. 
Another mechanism by which androgens could affect pituitary prolactin 
secretion is through the aromatization of testosterone to estrogen. Castrated rats 
treated with DHT exhibited higher stress-induced prolactin levels compared to 
gonadectomized males. However, administration of DHT was not sufficient to restore 
post-stress prolactin titers to that of stressed sham animals even though plasma DHT 
levels were higher than in intact (i.e., sham-operated) animals. Intact animals have 
circulating testosterone while DHT-treated castrates do not. Testosterone can either 
bind to the androgen receptor, be reduced to DHT and bind to the androgen receptor, 
or can be aromatized to 17~-estradiol and bind to the estrogen receptor (for review 
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see McEwen and Parsons, 1982). Since DHT cannot be aromatized to 17/j-estradiol, 
this steroid acts only through the androgen receptor. Thus, our data are consistent 
with the hypothesis that testosterone increases prolactin release, in part, through 
aromatization to 17/j-estradiol. Estrogen treatment of male or female rats results in 
anterior pituitary gland growth and hyperprolactinemia (Chen and Meites, 1970; Ajika 
et al., 1972; De Lean et al., 1977; Elias and Weiner, 1987; Cronin et al., 1982; 
Perez et al., 1986; Handa and Rodriguez, 1991). This is, in part, a result of 
lactotroph hypertrophy and hyperplasia as a consequence of decreased hypothalamic 
dopamine secretion (Elias and Weiner, 1987; Cronin et al., 1982; Perez et al., 1986). 
There is evidence demonstrating a direct anterior pituitary site of action of estrogen 
on prolactin secretion (Palka et al., 1966; Nicoll and Meites, 1964; Raymond et al., 
1978). However, the possibility that the hypothalamus is also an important site of 
control of prolactin secretion by estrogens cannot be excluded (Kanematsu and 
Sawyer, 1963; Ramirez and McCann, 1964; Ahren et al., 1971; Hokfelt and Fuxe, 
1972). It also remains to be determined whether androgens and estrogens act 
synergistically to influence anterior pituitary physiology. 
It is of interest to speculate on the physiological significance of androgen's 
effect on post-stress plasma prolactin levels. High levels of plasma prolactin may 
enhance immune function (Spangelo et al., 1987; Cross et al., 1989; Dardenne et al., 
1989; Mukherjee et al., 1990). Thus, the increased prolactin levels observed 
following stress may protect the organism from stress-induced immune suppression. 
Following the exposure to stressful stimuli, circulating androgens maintain the 
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secretion of prolactin and thereby, may indirectly influence the immune system. 
Moreover, since corticosterone is immunosuppressive (for rev. see Cupps and Fauci, 
1982), the increased plasma corticosterone response to stress in the castrate could 
conspire with a decreased prolactin response to suppress immune function. 
Plasma renin activity and plasma renin concentration were significantly 
increased following conditioned stress in all treatment groups. This is consistent with 
previous studies (Richardson-Morton et al., 1989, Van de Kar et al., 1984; Van de 
Kar et al., 1985). Plasma renin activity and concentration were not altered by 
gonadectomy in either stressed or control castrated animals. The secretion of renin 
from the kidney following exposure to stressful stimuli is thought to be caused by 
both sympathetic activation (for rev. see Reid et al. , 1986) and a blood-borne renin-
releasing factor (Urban et al., 1992). The secretion of this hypothalamic factor is 
thought to involve both serotonergic (acting via a 5-HT2 receptor) and 
catecholaminergic inputs to the PVN (Van de Kar, 1991, Richardson-Morton et al., 
1990). Our results suggest that these systems are not altered by circulating 
androgens. 
Conditioned stress led to an increase in the number of fecal boli defecated in 
the chamber during the 10 minute testing procedure. Circulating androgens do not 
influence the defecation of stressed rats since no difference was observed between 
gonadectomized males and DHT-treated castrates. Thus, the autonomic output 
influencing gastrointestinal activity was not affected by altering circulating androgens. 
As expected, conditioned stressed animals displayed a significant increase in 
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the duration of freezing behavior and significant decreases in the duration of sniffing, 
grooming, and rearing and the frequency of rearing and locomotor behaviors 
compared to non-shocked controls. No differences were seen among the treatment 
groups in animals exposed to conditioned stress. This is not altogether surprising 
when one considers that the stressed animals display a maximum of stress-like 
behaviors leaving little room for variation. For example, stressed rats exhibited 
freezing for approximately 90% of the time they were within the chamber (Figure 
27A). Treatment differences were, however, seen among the non-stressed controls. 
Non-stressed DHT-treated castrates exhibited more freezing and less sniffing, 
grooming, rearing, and locomotor activities compared to non-shocked intact and 
gonadectomized animals. Since the control rats were placed in the chamber for four 
consecutive days (without being shocked), they were exposed to a mild amount of 
stress inherent to the procedure. This mild stress is evident in plasma corticosterone 
levels when one compares home cage control rats with rats subjected to this procedure 
(home cage co~trols, 0.8 + 0.2 µg/dL; non-shocked controls, 3.0 + 0.8 µg/Dl; 
conditioned stress, 12.9 + µg/Dl; Van de Kar, unpublished data). Thus, DHT-
treated castrates exhibited more "fear-like" behavior in response to this mild stressor 
compared to intact and castrated rats. Differences between DHT-treated castrates and 
intact animals could be attributed to the higher levels of DHT in the DHT-treated 
castrates (Table 5) and/or to the nonaromatizable nature of DHT. 
In summary, the data suggest that circulating androgens are necessary for a 
normal response to conditioned stress. Removal of circulating gonadal androgens 
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enhances the ACTH and corticosterone responses and attenuates the plasma prolactin 
response to conditioned stress. Also, androgens may potentiate the behavioral 
response to stress. The absence of gonadal androgens does not influence plasma renin 
activity and concentration or defecation following conditioned stress. Thus, 
circulating androgens differentially modulate the neural systems responsible for 
expression of various components of the stress response. One major implication of 
this study shoud be emphasized. To date, most studies investigating the effect of 
gonadal hormones on the stress response have sampled only one or two parameters of 
the stress response. This study indicates that circulating andrognes differentially 
influence various components of the stress response. Examination of only one aspect 
of the stress response, such as ACTH and/or corticosterone, may be misleading. 
Depending on the parameter measured, subjects may appear less stressed, more 
stressed, or unaffected by a particular treatment. Thus, evaluating other 
neuroendocrine as well as autonomic and behavioral reactions to experimental 
challenge may be necessary to more accurately determine how an organism is reacting 
to stress. 
CHAYI'ER VII 
GENERAL DISCUSSION 
Summary 
Circulating gonadal steroids have been demonstrated to influence the 
hypothalamo-pituitary-adrenal (HPA) axis (Kitay, 1963; Critchlow et al., 1963; 
Gaskin and Kitay, 1971; Coyne and Kitay, 1971; Viau and Meaney, 1991a; Viau and 
Meaney, 1991b; Burgess and Randa, 1992; Randa et al., 1994). While estrogen 
enhances RPA activity (Kitay, 1963; Viau and Meaney, 1991a; Burgess and Randa, 
1992), circulating androgens may suppress activity of the RPA axis (Critchlow et al., 
1963; Gaskin and Kitay, 1971; Randa et al., 1994). The first experiment of this 
dissertation tested the hypothesis that androgens influence the RPA axis by reducing 
hypothalamic levels of CRH. It was observed that hypothalamic CRH content is 
increased in the male rat 3 weeks after bilateral gonadectomy. Treatment of 
gonadectomized male rats with the non-aromatizable androgen, dihydrotestosterone 
(DHT), normalizes CRH content to that seen in intact animals. Greater than 10 days 
of castration was necessary in order to observe a change in hypothalamic CRH 
content. Furthermore, three weeks after surgery, gonadectomized male rats had 
significantly more CRH-immunoreactive (IR) cell numbers in the paraventricular 
nucleus of the hypothalamus (PVN) compared to ORT-treated castrates. Thus, these 
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data indicate that the effect of androgens on the HPA axis occurs, at least in part, at 
the level of the hypothalamus. 
The second experiment was performed to determine whether the influence of 
androgens on CRH content and CRH immunoreactivity in the hypothalamus are a 
consequenc of changes in CRH gene expression. Corticotropin-releasing hormone 
mRNA levels in the PVN of intact, gonadectomized, and gonadectomized, DHT-
treated male rats were evaluated using in situ hybridization histochemistry. 
Corticotropin-releasing hormone mRNA levels in the hypothalamic paraventricular 
nucleus, however, were not altered 10 days or 3 weeks after gonadectomy. Thus, 
changes in CRH peptide levels cannot be explained by concurrent changes in mRNA 
levels or by a transient elevation in CRH mRNA preceding the alteration of peptide 
content. 
The third experiment tested the hypothesis that androgens regulate CRH by 
acting directly within CRH expressing neurons of the PVN. The regulation of 
cellular processes by androgens requires the presence of the androgen receptor (AR) 
which acts as a ligand-responsive transcription factor. In order for androgens to 
directly regulate hypothalamic CRH, AR must be expressed within CRH containing 
neurons. Thus, this study tested for the presence of AR immunoreactivity within 
CRH neurons of the PVN in male rats. The results of this experiment suggest that 
CRH containing neurons of the PVN do not contain AR immunoreactivity. Thus, it 
is likely that androgens influence CRH content via a transsynaptic mechanism. 
The final study was designed to determine whether circulating androgen~ 
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influence neuroendocrine, autonomic, and behavioral responses to a psychological 
stressor. The effects of conditioned stress were examined in male rats that were 
intact, gonadectomized, or gonadectomized and treated with DHT. Consistent with 
previous studies (Coyne and Kitay, 1971; Handa et al., 1994), the ACTH and 
corticosterone responses to conditioned stress were enhanced in gonadectomized male 
rats. However, the prolactin response to conditioned stress was suppressed in rats 
deprived of circulating gonadal androgens. Furthermore, DHT-treatment increased 
the expression of stress-associated behaviors. Thus, circulating androgens 
dijferen.tially influence neuroendocrine and behavioral responses to conditioned stress. 
Circulating androgens may selectively modulate the neuronal circuitry responsible for 
mediating various aspects of the stress response. 
Possible Mechanisms of Androgen Action 
The HPA Axis 
Androgens suppress HPA activity via central mechanisms. The loss of 
circulating gonadal androgens induces an increase in hypothalamic CRH content. 
This increase may explain the enhanced ACTH and corticosterone responses to 
physical and psychological stressors previously observed in the gonadectomized male 
rat (Coyne and Kitay, 1971; Handa et al., 1994). Also, anterior pituitary sensitivity 
to CRH is not altered in the gonadectomized male rat (Handa et al., 1994). Thus, 
androgens may act on a central nervous system (CNS) site(s) to alter HPA activity. 
Several mechanisms could explain the regulation of hypothalamic CRH by 
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androgens. Possibilities include an increased synthesis or half-life of CRH or a 
decrease in axoplasmic transport and/or secretion following gonadectomy. The 
possibility that axoplasmic transport and secretion of CRH are decreased following 
castration can be excluded due to the fact that the ACTH and corticosterone responses 
to stress are increased in the gonadectomized male rat (Coyne and Kitay, 1971; 
Handa et al., 1994). The possibility remains that synthesis in the soma or 
degradation of the peptide can be influenced by circulating androgens. Circulating 
androgens could decrease CRH peptide half-life or reduce the translational efficiency 
of CRH in parvocellular PVN neurons. 
In the second experiment, CRH mRNA levels in the PVN were not altered 10 
days or 3 weeks after gonadectomy. However, it is possible that changes in 
hypothalamic CRH content observed after gonadectomy are the result of an alteration 
of CRH gene expression. This hypothetical change in CRH gene expression might 
occur only in a small subset of cells and thus would be masked by a lack of change 
elsewhere in the PVN. Also, 10 days and 3 weeks after gonadectomy may not be the 
appropriate time to see such a change. 
If the increase in CRH content after gonadectomy is the result of changes in 
gene expression, one might observe this change by measuring CRH mRNA after a 
stressor. During homeostasis, CRH is stored in median eminence terminals and is 
secreted in relatively small amounts in response to a circadian pacemaker (Dallman et 
al., 1977). The presence of a real or perceived threat to the organism causes 
secretion of CRH into the hypophysial portal circulation. Following stress, CRH 
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mRNA increases in the medial parvocellular region of the PVN (Lightman and 
Young, 1988; Lightman and Young, 1989). This most likely represents an increase 
in the synthesis of CRH to replenish CRH stores released during stress. Presumably, 
CRH is synthesized in PVN neurons until the releasable pools of CRH are restored to 
pre-stress levels. In the castrated male rat, the size of the releasable pools of median 
eminence CRH may be greater than in the intact male rat. In the final study of this 
dissertation, the CORT and ACTH responses to stress were enhanced in the castrated 
male on the fourth day of exposure to a stressor. Thus, it appears that the larger pool 
of CRH in the castrated male is rapidly regenerated after a stressor. Therefore, if 
changes in CRH gene expression are responsible for androgen's effect on 
hypothalamic content of this peptide, this may be best observed after a stressor. 
Androgen regulation of CRH neurons of the PVN is indirect. Androgen 
receptor immunoreactivity was not observed within CRH expressing neurons of the 
PVN. Circulating androgens may act on other CNS neurons to modify levels of 
glucocorticoid or mineralocorticoid receptors and/or some neuromodulator which 
ultimately alters the pools of CRH stored in median eminence terminals. The PVN is 
a highly integrated and regulated cell group (for rev. see Swanson and Sawchenko, 
1983), and there are many possible target sites at which steroids could act to 
ultimately regulate CRH cells within the PVN. Several CNS sites have androgen 
responsive neurons and project to the PVN. These sites include limbic regions such 
as the bed nucleus of the stria terminalis (BNST) and the septum as well as brainstem 
sites such as the midbrain raphe (Sar and Stumpf, 1977; Swanson, 1987). 
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It is also possible that androgen responsive cells such as those in the 
hippocampus modify hypothalamic CRH content via a multisynaptic pathway. 
Interestingly, it has been reported that implantation of the synthetic glucocorticoid, 
dexamethasone, into the hippocampus results in a slight decrease in the 
adrenalectomy-induced effects on CRH immunoreactivity (Kovacs et al., 1986) while 
no effect was seen on CRH mRNA (Kovacs and Mezey, 1987). Androgens may act 
on the hippocampus to similarly influence hypothalamic CRH. 
This putative effect of androgens on the hippocampus may contribute to the 
enhanced activity of the HP A axis observed in the aged male rat. Extensive research 
has demonstrated an effect of adrenal steroids on the destruction of hippocampal 
neurons. ACTH or cortisone treatment of guinea pigs causes necrosis of pyramidal 
neurons of the hippocampus (Aus der Muhlen and Ockenfels, 1969). Furthermore, in 
the rat, aging results in the loss of some pyramidal neurons in the hippocampus 
(Landfield, 1987). This loss can be reduced by adrenalectomy in mid-life (Landfield, 
1987). Daily injections of corticosterone to young adult male rats mimicks the 
neuronal loss observed during aging (Sapolsky et al., 1985). Excitatory amino acids 
play an important role in this pyramidal cell loss (for rev. see Sapolsky, 1990). 
Corticosterone exacerbates kainic acid-induced hippocampal damage (Sapolsky, 1986), 
and glucocorticoids enhance the excitatory amino acid-induced loss of hippocampal 
neurons in culture (Sapolsky et al., 1988). Moreover, extensive research has 
provided evidence that the activity of the HP A axis is enhanced in the aging male rat 
(for rev. see McEwen, 1992). Since there is significant evidence implicating .the 
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bippocampus in the feedback inhibition of the HPA axis (for rev. see Jacobsen and 
Sapolsky, 1991), the "glucocorticoid cascade hypothesis" of stress and aging was 
generated in an attempt to formulate a causal relationship between the activity of the 
HP A axis and the deleterious actions of glucocorticoids on the viability of neurons in 
the hippocampus (for rev. see Sapolsky et al., 1986). It is possible that circulating 
androgens contribute to the enhanced activity of the HP A axis observed in the aged 
male rat. Studies in this dissertation and elsewhere (Critchlow et al., 1963; Gaskin 
and Kitay, 1971; Banda et al., 1994) demonstrate that circulating androgens inhibit 
HP A activity. Moreover, circulating androgens are known to decline in the aging 
male rat (Kaler and Neaves, 1981). Interestingly, a recent report suggests that 
circulating androgens protect hippocampal neurons from the N-methyl-D-aspartic acid-
(NMDA-) induced loss of membrane activity (Pouliot et al., 1993). This suggests 
that circulating androgens may influence glutamatergic responses in hippocampal 
pyramidal neurons to ultimately inhibit HP A activity. Thus, loss of cirulating 
androgens may contribute to the enhanced activity of the HP A axis in the aging male 
rat. 
The Stress Response 
In the final study of this dissertation (Chapter VI), several indices of the stress 
response were evaluated in terms of possible androgen regulation. The various 
components of the stress response are controlled by overlapping but different neuronal 
pathways. For example, serotonin stimulates the secretion of CRH and putative 
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prolactin- and renin-releasing factors (for rev. see Van de Kar, 1991). CRH secretion 
is also stimulated by catecholamines and acetylcholine and inhibited by GABA and 
opioid peptides (for rev. see Owens and Nemeroff, 1991). Furthermore, prolactin 
release from the pituitary is tonically inhibited by dopamine (Ben-Jonathon, 1985). 
Thus, the evaluation of several indices of stress may make it possible to gain insight 
into where and how androgens may be acting to alter the stress response. The 
absence of circulating gonadal androgens enhanced the ACTH and corticosterone 
responses and attenuated the prolactin response to conditioned stress. The non-
aromatizable androgen, DHT, increased the expression of stress-like behaviors. The 
renin response to conditioned stress was not altered by circulating androgens. 
In addition to the data from this study, hypotheses can be formed based on the 
results of a study localizing androgen receptor immunoreactivity to peptidergic 
neurons of the forebrain (Chapter V). In this experiment, androgen receptor 
immunoreactivity was observed within galanin expressing cells of the ventrolateral 
BNST. Testosterone regulation of galanin gene expression in the BNST has been 
reported (Miller et al., 1993a). Cells in the ventrolateral BNST have been 
demonstrated to project to the PVN (Sawchenko and Swanson, 1983). Ibotenic acid 
lesion of the ventrolateral BNST attenuates the stress-induced increases in ACTH, 
corticosterone, and prolactin without influencing the renin response to stress (Gray et 
al., 1993). Interestingly, infusion of galanin into the PVN attenuates the stress-
induced increase in plasma ACTH (Hooi et al., 1990), and galanin has been shown to 
have a regulatory role in the secretion of prolactin (Koshiyama et al., 1987; 
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Nordstrom et al., 1987; Ottlecz et al., 1988). 
Galanin may alter an organisms response to stress through its actions on other 
central neurotransmitter systems. In the central nervous system, galanin is known to 
influence noradrenergic, serotonergic, and cholinergic systems (for rev. see Bartfai et 
al., 1993). For example, studies in rat indicate that intracerebroventricular injections 
of galanin potently stimulate the serotonin metabolism in the hippocampus and median 
eminence (Sundstrom and Melander, 1988). Moreover, galanin appears to increase 
the affinity of 5-HT1A receptors for serotonin (Fuxe et al., 1988). Substantial 
evidence suggests that 5-HT1A receptors are involved in the serotonin-induced 
secretion of ACTH but not in the serotonin-induced secretion of renin (for rev. see 
Van de Kar, 1991). Furthermore, 5-HT1A receptors may play a role in the expression 
of CRH-induced behavior (Lazosky and Britton, 1991), a putative analogue of stress-
induced behavior (Koob et al., 1993). 
Taken together, these studies suggest the possibility that androgens may alter 
the response to stressful stimuli through its regulation of galaninergic and ultimately 
serotonergic systems. Clearly, androgens could be acting on any number of 
neuroanatomical and neurochemical systems to affect changes in the response to 
stress. However, future studies evaluating androgen regulation of galaninergic and 
serotonergic transmitter systems may be useful in determining the mechanism(s) by 
which androgens alter the physiological and behavioral responses to stress. 
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Implications and Conclusions 
The integrity of the HP A axis is essential for a normal response to threatening 
stimuli. Abnormal funtion of the HPA axis has been associated with psychological 
disorders such as depression (Kalin and Dawson, 1986) and panic disorder (Henry, 
1990). For example, depression is often brought on by stressful episodes (Paykel, 
1979) and has been associated with excessive secretion of HPA hormones (Kalin and 
Dawson, 1986). 
In humans, depression and panic disorder occur much more often in females 
than in males (Weissman and Klerman, 1977; Katschnig and Amering, 1990). 
Correspondingly, experimental data in rats reveal a sex difference in the 
corticosterone response to stress (Kitay, 1961). Several studies have indicated that 
estrogen acts to enhance HPA activity (Kitay, 1963; Viau and Meaney, 1991a; 
Burgess and Handa, 1992) while androgens may inhibit activity of the HPA axis 
(Critchlow and Kitay, 1963; Gaskin and Kitay, 1971; Handa et al., 1994; Bingaman 
et al., 1994). Thus, while estrogen may play an important role in predisposing a 
female to such disorders, androgens may protect a male from dysfunction of the stress 
response. 
These phenomena are also important in light of the various conditions 
involving altered gonadal function as well as behaviors which have been linked to 
HPA dysfunction. For example, Klinefelter's Syndrome, a genetic disorder present in 
1 in 1000 male births (Baker et al., 1976), is marked by unusually low testosterone 
levels throughout life (Schwartz and Root, 1991). Klinefelter males often exhibit 
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extreme depression (Nielsen et al., 1988; Schwartz and Root, 1991). Also, in the 
elderly, gonadal hormones are known to diminish (Kaler and Neaves, 1981; Baker et 
al., 1976) while the HPA response to stress is exaggerated (Sapolsky et al., 1984b). 
Moreover, a higher incidence of depression is seen among the elderly (Sorensen and 
Stromgren, 1961). One might contend that other factors (death of a spouse, low 
income, reduced mobility, etc.) may be the cause of depression in the elderly. 
However, it is possible that the stress associated with these factors, and the 
inappropriate biological response to that stress, could be involved in the onset of 
depression. 
It is important to note that most studies investigating the effect of gonadal 
hormones on the stress response have sampled only one or two parameters of the 
stress response. In the final study of this dissertation, the effects of circulating 
androgens on neuroendocrine, autonomic, and behavioral indices of stress were 
evaluated in order to determine whether androgens selectively or globally modulate 
the expression of various parameters of the stress response. Interestingly, removal of 
circulating gonadal androgens enhanced the ACTH and corticosterone responses and 
attenuated the plasma prolactin response to conditioned stress. Also, while androgens 
potentiated the behavioral response to stress, the absence of gonadal androgens did not 
influence plasma renin activity and concentration or defecation following conditioned 
stress. Circulating androgens differentially modulate the neural systems responsible 
for expression of various components of the stress response. Thus, examination of 
only one aspect of the stress response such as ACTH and/or corticosterone may be 
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misleading. Evaluating other neuroendocrine as well as autonomic and behavioral 
reactions to stress may be necessary in order to determine how an organism is 
reacting to environmental perturbation. It may be important for researchers to sample 
several indices of stress in order to gain a more accurate "profile" of the stress 
response. 
It should also be emphasized that gonadal steroids do not cause a female to be 
"more stressed" or "less stressed" than a male. Gonadal steroids cause males and 
females to be stressed differently from each other. That is, males may exhibit more 
stress-like behaviors and less of an HPA response to stress. Furthermore, other 
hormonal and autonomic responses to stress may be more or less in males compared 
to females. Thus, females may be more susceptible to depression, not because they 
are "more stressed" than males beut rather because they respond to stressful stimuli 
differentally than males. 
The studies in this dissertation have demonstrated that circulating gonadal 
androgens play an important role in the regulation of an organism's response to 
environmental perturbation. Circulating androgens suppress the HPA axis via central 
mechanisms. In contrast, androgens have a facilitatory effect on prolactin secretion. 
These effects are quite pronounced when the animal is challenged with a stressor. In 
the absence of circulating androgens the machinery with which an organism copes 
with its environment is weakened, and exposure to either physical or psychological 
stress brings out that weakness. In this manner, an inadequate gonadal steroid 
secretion can lead to pathological conditions like depression. Future studies of the 
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site(s) and mechanism(s) of androgen action will not only provide an understanding of 
gonadal influences on the physiological adaptation to stress, but may be important in 
providing an understanding of the biological basis underlying behaviors such as 
depression. 
This dissertation also points out the importance of testosterone as a regulator 
of evolution. Survival of the organism and survival of the species are of utmost 
importance. Obviously, testosterone acts to contributes to the survival of a species by 
directly regulating reproduction. However, circulating testosterone may indirectly 
enhance both survival of the species and survival of the organism through its 
regulation of the stress response. Since products of the HP A axis inhibit reproductive 
function (Plas-Rose and Aron, 1981; Sirinathsinghji et al., 1983; Rivier and Vale, 
1984; Rivier and Vale 1985b; Rivier et al., 1986; Armstrong, 1986; Sirinathsinghji et 
al., 1986; Kamel and Kubajak, 1987), circulating testosterone indirectly enhances 
reproduction by inhibiting HP A activity. In this manner, circulating androgens 
indirectly enhance survival of the species. Additionally circulating testosterone 
potentiates the prolactin response to stress. Since prolactin is thought to enhance 
immune function (Spangelo et al., 1987; Cross et al., 1989; Dardenne et al., 1989; 
Mukherjee et al., 1990) circulating testosterone may indirectly enhance the survival of 
the organism through it's regulation of the prolactin response to stressful stimuli. It 
seems appropiate that testosterone would play this major role in the evolution process. 
An organism contributes to the evolution of its species during and prior to its 
reproductive stage. What better mediator of the evolutionary process than 
testosterone, a hormone that is only produced in great amounts during a male's 
reproductive stage. Clearly, circulating androgens represent a major mediator of 
evolution. 
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